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♫ You can get it if you really want  
You can get it if you really want ♪ 
♫ You can get it if you really want  
But you must try ♫ 
♪ Try and try 
♫ Try and try ♪ 
You'll succeed at last. ♫ 
(Jimmy Cliff)  
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 Zusammenfassung 
1 Zusammenfassung 
Temporallappenepilepsie (TLE) verbunden mit hippokampaler Sklerose ist eine weit 
verbreitete Erkrankung des Zentralnervensystems. Häufig ist bei dieser Form der 
Epilepsie die Behandlung der Anfälle durch eine so genannte Antiepileptika-Resistenz 
erschwert, wenn nicht gar gänzlich verunmöglicht. Die Ursachen dieser 
Pharmakoresistenz sind unklar. Eine Hypothese, die Transporter-Hypothese, besagt 
dass eine verstärkte Beseitigung von Antiepileptika aus dem epileptischen Fokus zu 
einer unzureichenden Medikamentenkonzentration führt. Der Abtransport der 
Medikamente an der Blut-Hirn Schranke (BHS) läuft vermutlich über sogenannte 
Multidrug-Transporter, vor allem der ABC-Transporter Familie. Es ist daher wichtig zu 
untersuchen, ob ein Antiepileptika ein Substrat für solche ABC-Transporter ist, um 
vorhersagen zu können, wie die Medikamente unter physiologischen wie auch 
pathologischen Bedingungen im Hirn verteilt sind. Dies ist die Grundlage, um 
zukünftig Medikamente mit verbesserter Penetration des Gehirns und stärkerer 
Wirksamkeit zu entwickeln. In dieser Arbeit wurde untersucht, welche Rolle Multidrug-
Transporter der ABCB, sowie der ABCC Familie, in der Pharmakoresistenz gegen 
Antiepileptika spielen. Wir benutzten einen in vitro sowie einen in vivo Ansatz. 
Einerseits haben wir ein neuartiges in vitro BHS Modell entwickelt. Dieses besteht aus 
polarisierten Epithelzellen (MDCK Zellen) welche mit einer, mittels Doxycyclin 
induzierbaren, Expressionskassette für die humanen ABC-Transporter ABCB1 und 
ABCC1 stabil transfiziert wurden. Die Zellen bilden dichte Monolayers. Daher wird ein 
sogenanntes Zwei-Kompartiment-System mit zwei getrennten Hälften gebildet, wenn 
die Zellen auf einem Filtereinsatz wachsen. Der Zellrasen bildet dabei eine selektive 
Barriere. Nachdem monoklonale, stabil transfizierte Zelllinien erzeugt worden waren, 
wurden in diesem System Transportstudien durchgeführt. Zuerst verifizierten wir die 
induzierbare Expression und korrekte Lokalisation der rekombinanten Transporter 
mittels Western Blot und Antikörperfärbung der Zellen, dann überprüften wir die 
Funktionsfähigkeit, indem wir den Transport eines bekannten Substrats testeten. Für 
die Transportstudien wurde, eine bestimmte Zeit nach der Zugabe eines Stoffes in 
eines der Kompartimente, die Stoffmenge in den verschiedenen Kompartimenten 
mittels LC-MS/MS ermittelt. Durch den Vergleich des Transports in Zellen, welche den 
Transporter überexprimieren, mit dem in nicht-induzierten Zellen, wurde ermittelt, 
welchen Anteil die überexprimierten Transporter an den Gesamttransport haben. Für 
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die beiden getesteten Antiepileptika Carbamazepin (CBZ) und Lamotrigin konnte kein 
Transport, weder durch ABCB1 noch durch ABCC1, gezeigt werden. Hieraus wurde 
geschlossen, dass beide entweder keine oder nur sehr schwache Substrate der 
getesteten humanen ABC-Transporter sind. Erstaunlicherweise wurde jedoch 
beobachtet, dass alle getesteten Substanzen, unabhängig von der Expression der 
induzierbaren ABC-Transporter, aktiv (da stärker bei 37°C als bei 4°C) durch die 
MDCK Zellen transportiert wurden und zwar in basolateral-nach-apikaler Richtung. 
Dies widerspiegelt wohl die physiologische Funktion der endothelen Nierenzellen, von 
denen die MDCK Zellen abstammen, und legt die Vermutung nahe die Folge von 
endogen exprimierten Transportern unterschiedlichen Typs zu sein.  
Im zweiten Ansatz testeten wir die Transporter-Hypothese der Pharmakoresistenz in 
vivo, in einem Medikamenten-resistenten Mausmodell der Temporallappenepilepsie. 
Dazu wurden wildtyp und knockout Mäuse, welchen die Gene für abcb1a fehlen, 
benutzt. Diese Mäuse wurden durch intrahippokampale Injektion von Kainat (KA) 
epileptisch gemacht. Nachdem intrahippokampale Elektroden implantiert worden 
waren, konnten die EEGs dieser Mäuse gemessen und analysiert werden. Der Effekt 
einer Injektion von unterschiedlichen Dosen von CBZ wurde mit dem Effekt des 
Trägerstoffs allein verglichen. Hierfür wurde die Anzahl und Dauer der Anfälle vor und 
nach den Injektionen analysiert. Alle Mauslinien zeigten drei Wochen nach der KA 
Injektion die charakteristischen Anfälle sowie eine hippokampale Sklerose. Wir fanden 
klare Unterschiede zwischen den verschiedenen getesteten Mausstämmen in der 
Anfallszahl, aber nicht in der Anfallslänge. Es schien auch so, als ob die Mäuse nach 
der Injektion von CBZ gehäuft interiktale Aktivität hätten. Nichtsdestotrotz konnte 
keine Beteiligung von Abcb1a an der CBZ-Resistenz nachgewiesen werden.  
Mittels Kombination der beiden Studien sollte die Gültigkeit der Transporter-
Hypothese für die Antiepileptika-Resistenz überprüft werden. Die Resultate stützen 
die Hypothese nicht, da in vitro keine Beteiligung der humanen Proteine ABCB1 und 
ABCC1 am Transport von Antiepileptika gezeigt werden konnte, noch konnte in vivo 
bewiesen werden, dass das Maus-Homologon Abcb1a eine Rolle bei der Resistenz 
spielt. Zusammen mit ähnlichen Befunden von anderen Forschungsgruppen stellen 
diese Resultate die Relevanz der Transporter-Hypothese in Frage. Man muss 
annehmen, dass nicht nur ein Mechanismus für die Antiepileptika-Resistenz in 
Patienten verantwortlich ist, sondern dass verschiedene zusammenspielen, 
einschliesslich die Beseitigung von Medikamenten durch deren Abfuhr oder deren 
Metabolismus, sowie funktionale Veränderungen der Wirkungsorte.  
 6 
 Summary 
2 Summary 
Temporal Lobe Epilepsy (TLE) with hippocampal sclerosis is a common adult seizure 
disorder, with resistance to antiepileptic drugs (AED) being a common limiting factor 
of its treatment. Pharmacoresistance might be due to enhanced AED removal from 
epileptogenic tissue at the blood-brain barrier (BBB) through over-expression of 
multidrug transporters, especially of the ABC transporter family. Hence, evaluation of 
the potential of an AED to be a substrate for ABC transporters located at the BBB will 
be crucial to understand its brain distribution under normal and pathological 
conditions and for future development of drugs with improved brain penetration. This 
work investigated the possible role of multidrug transporters of the ABCB and ABCC 
family in AED resistance using an in vitro and an in vivo approach. 
We have established a novel in vitro BBB model using inducible expression of the 
human ABC transporters ABCB1 and ABCC1 in stably transfected polarised epithelial 
cells (MDCK cells). These cells build tight monolayers, hence forming a selectively 
permeable barrier separating a basal from an apical compartment when grown on 
filter inserts in cell culture wells. Transcellular diffusion or transport, either facilitated 
or active, are required for a substance to cross from one compartment to the other. 
With this system, it is therefore possible to assess the substrate specificity of any 
recombinantly expressed transporter. Furthermore, inducible expression by 
doxycycline allows using non-induced cells as a control. Monoclonal lines, transfected 
with cDNA constructs, were selected using Western blotting and immunofluorescence 
to verify the level of overexpression and the correct subcellular localisation of the 
recombinant proteins. Transport was assessed by adding a compound of interest to 
one compartment and, after a certain incubation time at 37ºC, measuring its 
concentration in each compartment, as well as intracellularly by LC-MS/MS analysis. 
To distinguish between the action of the overexpressed transporter and endogenous 
transport mechanisms, experiments were performed in parallel with non-induced 
cells. In addition, control experiments were performed at 4ºC to inactivate energy-
dependent processes. The two first-line AEDs carbamazepine (CBZ) and lamotrigine 
could not be demonstrated to be substrates of either ABCB1 or ABCC1 under the 
condition of our assay. This result led to the conclusion that both drugs are weak 
substrates at best, of these human ABC transporters. Surprisingly, we observed that 
all these drugs and other compounds tested were transported through the MDCK cells 
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in basolateral to apical direction in a manner that was not influenced by the presence 
of the inducible ABC transporters. This feature might reflect the physiological function 
of epithelial kidney cells and is probably due to the expression of various endogenous 
transporters of various types. 
In a separate study, we tested the multidrug transporter hypothesis of 
pharmacoresistance in vivo in a mouse model of drug refractory TLE. We used wild 
type mice and knockout mice lacking the abcb1a gene, which were rendered epileptic 
using intrahippocampal kainate (KA) injection. Occurrence of chronic recurrent 
seizures was determined by intrahippocampal EEG recordings.  The efficacy of CBZ 
for suppressing seizures was compared to vehicle injection, by quantifying the 
frequency and duration of seizures before and after injection. All mouse lines 
displayed characteristic epileptic seizures combined with hippocampal sclerosis three 
weeks after KA injection. We found a marked strain-difference in seizure frequency 
but not seizure duration in response to CBZ. In addition, increased interictal activity 
was observed after CBZ injection. Despite these effects, an involvement of Abcb1a in 
resistance to CBZ could not be demonstrated unambiguously.  
By combining both approaches we aimed to assess the validity of the transporter 
hypothesis for AED resistance. Our results do not support the hypothesis, as no 
involvement in AED transport of human ABCB1 and ABCC1 was found in vitro, nor 
could the mouse homologue Abcb1a clearly be demonstrated to play a part in 
resistance to CBZ in vivo. Our results, together with comparable findings of other 
groups, questions the relevance of the multidrug transporter hypothesis. However, it 
is possible that multiple mechanisms, including extrusion and metabolism of drugs, 
and functional changes at drug targets, act together to result in drug resistance to a 
multitude of different AEDs. 
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3 General Introduction 
3.1 Epilepsy 
Epilepsy is a major neurological disorder which does not only affect humans, but is 
older than mankind. Not only the human brain, is complex enough to generate the 
typical synchronised discharges which underlie a seizure. Due to the generalised 
seizures which may be symptomatic and appear quite spectacular, people with 
epilepsies have often been stigmatised negatively or positively in history. In the 
ancient world people with epilepsy have been considered holy and the old Greeks 
even called it the “Sacred Disease”. Hippocrates was the first to state that it was not 
more or less sacred than any disease, but has a natural cause lying in the brain 
(Hippocrates, ca 400 BC). In the mediaeval period, seizures were often interpreted as 
demonic possessions and treated with Exorcism by the Catholic Church or affected 
people were burnt as witches. Etymologically the word “seizure” derives from “seize”, 
implying that a supernatural power has taken hold of the person. 
Even though today we know that neither devil nor God have much to do with 
epilepsy, we are still dealing with the same symptoms. The underlying seizures are 
caused by electromagnetic discharges in the brain. 
Epilepsy is a chronic and often progressive brain disorder and has a world prevalence 
of about 1 % (Shorvon, 1996, Browne, 2001). It is characterised by recurring, 
unpredictable seizures. These typically last seconds to minutes but can prolong to 
become a continuous status epilepticus. Often it can be controlled with medication 
and in many cases spontaneous remission occurs, however, there is no real cure 
(Cockerell et al., 1995). It should be understood as a group of syndromes rather than 
a single disorder. The mechanisms underlying epileptogenesis are not clear, though, 
seizure development involves synchronised, rhythmic firing of neurons. The driving 
forces, hypersynchronisation of the neuronal circuitry and a hyperexcitability of the 
neurons, can have numerous sources (see below). 
3.1.1 Pathology 
The causes for epilepsy are diverse and are classified into three groups. i) 
Symptomatic: caused by a known disorder of the central nervous system (CNS) 
including preceding brain damage through tumour, trauma or through drugs of abuse 
and toxins; Or related to parasitic diseases such as neurocysteriosis, schistotomiasis 
or malaria (Dua et al., 2006). ii) Idiopathic: with a genetic predisposition but without 
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a known CNS damage. iii) Cryptogenic: where the cause remains elusive. (Shorvon, 
1996, Avanzini and Franceschetti, 2003, Steinlein, 2004, Dua et al., 2006) 
Nevertheless, the boundaries between these forms are not strict and sometimes 
difficult to define.  
Several types of epilepsy are discerned. The classification can be done by cause, 
manifestation of seizures, localisation of origin of the seizures in the brain or by the 
trigger leading to a seizure. The seizure-types are also classified. The main division is 
between generalised seizures, which affect the whole brain, and partial seizures, 
where the source of the seizure can be localised to a certain brain area. Partial 
seizures are subdivided into complex and simple partial seizures, depending to what 
extent consciousness is affected. Simple partial seizures can also progress into 
complex partial seizures and may even evolve into so called secondary generalised 
seizures. Generalised seizures are characterised by synchronised activity of neurons 
from both hemispheres combined with a loss of consciousness. They are subdivided, 
depending on the effect on the body, into absence seizures also referred to as ‘petit 
mal’, myoclonic and clonic convulsive seizures, atonic seizures and tonic-clonic 
seizures, also known as ‘grand mal’, which is the most severe and palpable seizure 
type. (ILAE, 1981)  
Among the various different kinds of epilepsy, temporal lobe epilepsy (TLE) is the one 
with the worst prognosis. It is a form of partial epilepsy and results in focal seizures. 
Typically, patients who develop TLE have experienced a febrile seizure during early 
childhood. Histological analyses of surgical specimens from patients with TLE have 
revealed common occurrence of hippocampal sclerosis (HS) and focal mass lesion. HS 
is characterised by a selective neuronal cell loss and gliosis in the cornu ammonis 
(CA) region 1 (CA1) and the hilus, occasional dispersion of the granule cell layer of 
the dentate gyrus (DG) (Figure 3.1) as well as synaptic reorganisation of the mossy 
fibres (mossy fibre sprouting) (Thom, 2004). Incomplete seizure control is a major 
problem with up to 80 % or more affected TLE patients and often resection of the 
epileptic focus is the only possible treatment (Mattson et al., 1996, Stephen et al., 
2001, Wieser, 2004). It is debated whether the rearrangements in morphology and 
functionality, combined with astrogliosis may cause or contribute to drug 
refractoriness and persistence of seizures even after prolonged treatment. 
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Figure 3.1: Human hippocampus, healthy and with TLE. MRI overview of total healthy 
brain (C) and Nissl staining of human hippocampus cytoarchitecture from a control (autopsy) 
(A) and a TLE patient with HS (B). A: MRI with indication (arrow) of location of human 
hippocampus (box). B: Control, with a normal distribution of neuronal cell somata. C: TLE with 
HS, with prominent cell loss in CA1, CA3, and hilus (H) with relative sparing of the dentate 
gyrus (DG) granule cell layer and granule cell dispersion. The CA2 and part of CA3 pyramidal 
cell layer is not shown in this section. Adapted from (Loup et al., 2000). 
 
Seizures are in principal caused by hyperactive, synchronously firing neurons. The 
hyperactivity may be caused by a hyperexcitability of excitatory neurons. To generate 
action potentials, the ion distribution across the cell membrane and resulting 
transmembrane potential is crucial. If the balance is perturbed, e.g. through elevated 
extracellular K+ levels in the resting state, neurons may depolarise easier, leading to 
hyperexcitability. Hence, any system required for the maintenance and 
reestablishment of the resting potential after a depolarisation may lead to seizure 
activity when impaired, suggesting a role in epilepsy. One example is the Na+/K+-
ATPase, which, when blocked in hippocampal slices, can lead to epileptoform bursting 
activity in the CA1 region (Grisar et al., 1992, Vaillend et al., 2002). 
Voltage-gated ion channels which are involved in the maintenance of the polarisation 
of the cell membrane are prone to play a role in epileptogenesis as well. Thus, if for 
example, voltage-gated Na+ channels became activated at a more negative resting 
potential depolarisation would be facilitated which could potentially lead to a seizure. 
Indeed, various mutations in the subunits of voltage-gated ion channels have been 
linked to certain forms of epilepsy (Meisler et al., 2001, Avanzini and Franceschetti, 
2003, Steinlein, 2004).  
Another explanation for the development of seizures is a disturbance in the 
orchestration of inhibitory and excitatory synaptic transmission. To maintain proper 
brain function, the overall balance of excitatory and inhibitory neuronal activity must 
be maintained. Glutamate and acetylcholine (ACh) are excitatory neurotransmitters 
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whereas γ-amminobutyric acid (GABA) is the major inhibitory neurotransmitter of the 
CNS. Hyperexcitability may be caused by an imbalance of excitatory and inhibitory 
neurotransmitters, altered neurotransmitter signalling or a loss of inhibitory 
interneurons. GABA acts mainly via ligand-gated Cl- channels, the pentameric GABAA-
receptors. Their activation leads to opening of the channels which in turn increases 
the membrane conductance due to possible Cl- influx. This effect is known as 
shunting inhibition. Hence, a higher current is needed to change the membrane 
potential and to generate an action potential. In epilepsy, this inhibition may be 
lowered due to impaired GABA signalling by way of reduced levels of GABA or 
impaired sensitivity of the GABAA-receptor to the transmitter. Loss of function 
mutations in GABAA-receptor subunits as well as gain of function mutations in ACh-
receptors have been found in heritable forms of epilepsy (Steinlein, 2004). Further it 
is known that excessive release of glutamate causes excitotoxicity and leads to 
neuronal cell death in status epilepticus (Fujikawa, 2005). Nevertheless, the 
relationship between neurotransmitters and seizures might not be so simple because 
of the complexity of neuronal networks with feedback and feedforward inhibition and 
due to changes in membrane potential gradients especially during development as 
reviewed in (Steinlein, 2004, Scharfman, 2007). Susceptibility for seizure development 
may also arise from effects of neuromodulators such as adenosine. By activating 
adenosine A1 and A2A receptors, high adenosine levels in the brain lead to tonic 
inhibition which can be reversed by receptor antagonists such as caffeine. Activation 
of the receptors by selective agonists or adenosine delivery by implanted cells have 
been shown to suppress seizures. On the other hand, overexpression of adenosine 
kinase, the main adenosine metabolising enzyme in the brain, has been found to 
contribute to epileptogenesis. Concluding, epilepsy may be associated with a 
dysfunction of the adenosine-mediated inhibitory tone (Boison, 2008).  
3.1.2 Antiepileptic drugs 
Treating epilepsy has always been a challenge. Non-pharmacological treatments 
include the ketogenic diet, various types of electrical stimulations like vagus nerve 
stimulation or deep brain stimulation and avoidance therapy, just to name a few. A 
vast number of treatments and drugs have been developed since the middle of the 
19th century when in 1857 the first effective drug was found: Potassium bromide. 
Bromides enhance the sensitivity of GABAA receptors to GABA and increase GABAA 
receptor currents as they are more sensitive to Br- than to Cl- (Gallagher et al., 1978). 
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Bromides are still in use for treatment of epilepsy in cats and dogs and were the best 
anticonvulsants until 1912, when the first barbiturate, phenobarbital was introduced. 
Phenobarbital has since been the most widely used antiepileptic drug (AED) and is 
also the oldest which is still commonly used especially in developing countries. 
Barbiturates enhance the effect of GABA by increasing the mean opening time of 
GABAA-receptors, without affecting opening frequency or conductance but can also 
activate the receptor directly, in absence of GABA. This may also be the reason for 
the strong sedative effect of barbiturates (Kwan and Brodie, 2004). 
In 1938, phenytoin started to replace the barbiturates as it does not display the 
sedative side effect. Phenytoin belongs to the class of hydantoins and reduces 
electrical conductance between neurons by stabilizing the inactive state of voltage-
gated Na+-channels. This action is believed to explain the protective action against 
generalised tonic-clonic as well as partial seizures (Francis and Burnham, 1992, 
Glauser, 2001).  
Other AEDs acting on voltage-gated Na+ or Ca2+- channels include carbamazepine 
(CBZ) and its more recent, better tolerated derivative oxcarbazepine, of the 
carboxamides as well as the more recently introduced lamotrigine, a triazine. All three 
do also act as mood stabilisers and are used in treatment of bipolar disorders. CBZ 
and lamotrigine are still of the most widely used first line anticonvulsants used as 
monotherapy for simple and complex focal seizures as well as to treat generalised 
tonic-clonic seizures. Their modes of action are rather well understood. They stabilise 
the inactivated state of Na+ channels (Schmutz et al., 1994, Kuo and Lu, 1997, 
Ambrosio et al., 2001). In 2000 the sulphonamide Zonisamide came into use which is 
also thought to act on Na+- and Ca2+- channels (Leppik, 2004). 
Quite a few modern AEDs target the GABA system, just as the first drug, bromide, 
did. Commonly known are the benzodiazepines which act as CNS depressants. Their 
activity results from an allosteric modulation of GABAA receptors containing the γ2 
subunit together with α1, α2, α3, or α5. For the anticonvulsant effect, receptor 
subtypes containing the α1γ2 subunit combination are necessary (Rudolph et al., 
1999). Members of this drug family include diazepam, clonazepam or lorazepam 
(Table 3-1). However, due to strong side effects and dependence these drugs are 
mainly used for acute treatment of status epilepticus rather than long term 
prophylactic treatment.  
Vigabatrin is a GABA analogon which acts on a GABA transaminase and thereby leads 
to elevation of GABA levels in the brain. However, the effect seems not to depend on  
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GABAA receptor-mediated synaptic response but on tonic inhibition which is probably 
due to higher extracellular GABA levels (Rogawski and Loscher, 2004). Another AED, 
tiagabin, a fatty acid, inhibits the GABA transporter GAT1 thereby slowing reuptake 
and clearance of GABA from the synaptic cleft and prolonging inhibitory postsynaptic 
potentials (Thompson and Gahwiler, 1992). 
There are also a couple of drugs of with complex and/or mixed modes of action. E.g. 
valproate, also a fatty acid which was found to have anticonvulsant effects already in 
1962, seems to have multiple modes of action including blockage of voltage-gated 
Na+-channels and T-type Ca2+-channels and also to act on GABA catabolism as GABA-
transaminase inhibitor. These properties make valproic acid a broadband 
anticonvulsant drug. 
For a number of drugs the mechanisms of action are still elusive or only poorly 
understood. For example levetiracetam, a pyrrolidine, seems to act on N-type Ca2+ 
channels, thereby inhibiting Ca2+ currents and has been suggested to bind and 
modulate SV2A, an integral membrane protein which has a crucial role in the 
regulation of vesicle function (Lynch et al., 2004, Rogawski and Loscher, 2004). 
Levetriacetam was approved as anticonvulsant in 1999 and is especially used as an 
adjunctive therapy in adult patients for whom current therapies have not been 
effective in controlling partial seizures. 
The fructose derivative topiramate seems to have a multitude of actions such as 
activation of GABAA receptors, action on kainate and AMPA receptors and blocker of 
Na+ and Ca2+ channels (Privitera, 2001, Rogawski and Loscher, 2004). 
The GABA analogon gabapentin was designed to mimic the chemical structure of 
GABA. However, it lacks activity via GABAA receptors and its mode of action is poorly 
understood. Though, it binds to a subunit of high-voltage-gated Ca2+-channels 
(Rogawski and Loscher, 2004). 
Ethosuximide, a succinimide, is widely used in absence seizures (Table 3-1). There is 
some controversy over the exact mechanism by which it acts. However, it seems to 
be a T-type Ca2+-channel blocker (Rogawski and Porter, 1990). 
Research is still ongoing, ideally trying to find a cure for epilepsy, hence, taking in 
account genetic findings as well as various animal models of epilepsy. For future 
strategies of epileptic treatment, drug development is one possibility with the 
prospective that compounds with new modes of action will be developed. 
General Introduction  Epilepsy 
Table 3-1: Antiepileptic drugs used to treat partial seizures. 
Drug Action on: Protein F (%) Tmax Dose Chemical structure 
 Na+ 
channels 
Ca2+ 
channels
GABAergic 
system 
Glutamate 
receptors 
binding
(%) 
 (h) (mg/kg/d)  
Predominant Na+ (and Ca2+) channel activity 
Carbamazepine INaF    75 75 - 85 4 - 12 10 - 30 
(carboxamide) 
Oxcarbazepine INaF    45 > 90  15 - 30 
(carboxamide) 
Lamotrigine INaF HVA   55 > 90 1 - 3 1 - 15 
(triazine) 
Phenytoin INaF, INaP    90 > 90 2 - 12 5 - 10 
 (hydantoin) 
Zonisamide INaF T-type   55  2 - 5 4 - 8 
(sulfonamide) 
Mixed, complex or poorly understood actions 
Ethosuximide  T-type?   0 100 2 - 7 15 - 20 
 (succinimide) 
Gabapentin  HVA (α2δ) ↑ GABA 
turnover 
 0 30 - 60 2 - 3 30 - 40 
(GABA analogue) 
Levetiracetam  HVA reverses 
DMCM 
 ≤ 10 100 1 - 2 15 - 40 
(pyrrolidine) 
Phenobarbital  HVA GABAAR AMPA 45 > 90 0.5 - 4 2 - 5 
 (barbiturate) 
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Adapted from (Bourgeois, 2001, Rogawski and Loscher, 2004), (Delanty, 2001) and (Bourgeois, 2001). AMPA, α-ammino-3-hydroxy-5-methyl-4-
isoxazole-propionic acid; DMCM, methyl-6,7-dimethoxyl-4-ethyl-β-carboline-2-carboxylate (a negative allosteric modulator of GABAA receptors); 
F, bioavailability; GABA, γ-amminobutyric acid; GABAAR, GABAA receptor; h, hours; HVA, high voltage activated; INaF, fast Na+ current; INaP, 
persistent Na+ currents; KA, kainate; NMDA, N-methyl-D-aspartate; protein binding, fraction bound to serum proteins, Tmax, time interval 
ingestion to maximal serum concentration. aconcentration dependent; babsorption of enteric coated tablets is delayed 
Topiramate INaF, INaP HVA GABAAR KA/AMPA 15 > 90 1 - 4 5 - 9 
(fructose derivative) 
Valproate INaF?, INaP? T-type? ↑ GABA 
turnover 
 70 – 93a > 90 1 – 8b 15 - 30 
(fatty acid) 
GABA-mediated mechanisms 
Clonazepam   GABAAR 
allosteric 
modulation 
 85 ≥ 90 1 - 3 0.02 – 0.2 
(benzodiazepine) 
Diazepam   GABAAR 
allosteric 
modulation 
 95 > 90 1 0.2 – 0.5 
(benzodiazepine) 
Lorazepam   GABAAR 
allosteric 
modulation 
 90 > 90 1.5 - 2 0.03 
(benzodiazepine) 
Tiagabine   GABA 
transporter 
 96 > 90 1 - 2 0.1 - 1 
(fatty acid) 
Vigabatrin   GABA 
transporter 
  80 0.5 - 2 40 - 100 
(fatty acid) 
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3.1.3 Pharmacoresistance 
Despite the vast number of drugs and combinations of drugs with various chemical 
and pharmacological properties available, some patients do not respond to treatment. 
In these cases surgical removal of the epileptic focus, if possible, remains the last 
possibility. Pharmacoresistance in epilepsy is not easy to define, however, an 
important characteristic is that many patients with refractory epilepsy do not respond 
to several drugs (Regesta and Tanganelli, 1999). Just as the disorder itself, the 
resistance to AEDs is probably multifactorial.  Genetic factors may play a role, as well 
as disease related factors, such as aetiology, AED treatment or altered drug targets. 
On the other hand, the broad range of drugs with various modes of action argues 
against an epilepsy-induced alteration of specific targets but rather hints that non-
specific, adaptive mechanisms are involved.  
Three main hypotheses have been put forward so far: The change of drug target 
hypothesis, the enzymatic barrier hypothesis, and the multidrug transporter-mediated 
extrusion hypothesis. The first is characterised by reduced efficacy or affinity of an 
AED to its target. These include ion channels and neurotransmitter receptors, as well 
as enzymes involved in release, uptake and metabolism of neurotransmitters 
depending on the mode of action of AEDs (Schmidt and Loscher, 2005). One such 
mechanism found in animal models of epilepsy is channelopathy through a change of 
subunit composition in voltage gated ion channels. These are both, activated and 
inactivated by certain voltages. The current range between complete inactivation and 
the starting of activation is termed window current. Channelopathies may be leading 
to changes in Na+-channel voltage dependence. Hence, channels open more readily 
resulting in an increased window current. Consequential, a persistently active Na+ 
influx could amplify synaptic depolarisation (Ellerkmann et al., 2003, Schmidt and 
Loscher, 2005). 
The enzyme hypothesis has recently been put forward. Briefly, it was found that 
endothelial cells of the blood-brain barrier (BBB) from patients with refractory 
epilepsy express more of the functional cytochrome P450 enzyme Cyp3A4 which can 
convert e.g. CBZ to its first metabolite 10,11-dihydrocarbamazepine (Janigro, 2008). 
Furthermore other metabolising enzymes such as epoxide hydrolases have been 
found to be active in the BBB and circumventricular organs (Ghersi-Egea et al., 1994). 
The resulting metabolism of AEDs would prevent them from reaching their target. 
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The third hypothesis, known from cancer research, is enhanced extrusion of drugs 
from the brain through multidrug transporters. These, located at the BBB, could be 
over-expressed or otherwise up-regulated in patients and prevent sufficient uptake of 
AEDs into the brain (Loscher and Potschka, 2002, Kubota et al., 2006). Multidrug 
transporters are expressed at the BBB (Kubota et al., 2006, Soontornmalai et al., 
2006, Gazzin et al., 2008, Roberts et al., 2008) and their role in resistance is stressed 
by the fact that several studies claim to have found overexpression of multidrug 
transporters in epileptic brain tissue of patients and in epilepsy models (Tishler et al., 
1995, Sisodiya et al., 1999, Zhang et al., 1999, Dombrowski et al., 2001, Sisodiya et 
al., 2001, Sisodiya et al., 2002, Aronica et al., 2003, Aronica et al., 2004, Volk et al., 
2004). However, the data about transport substrates among AEDs is still scarce and 
controversial (Luer et al., 1999, Rizzi et al., 2002, Sills et al., 2002, Gibbs et al., 2004, 
Loscher, 2007, Luna-Tortos et al., 2008).  
3.1.4 Animal models of epilepsy  
To study epilepsy and AED action a multitude of acute and chronic models have been 
developed. Nevertheless, due to the fact that there are several types of epilepsies as 
mentioned above, it is not easy to come up with a relevant model for each form of 
the disorder. There are in vitro models, based on cell cultures, on rodent brain slices, 
on hippocampal slices or slice preparations from human brain specimens etc. On the 
other hand, there are a number of in vivo animal models for various types of epilepsy 
in various species including drosophila, zebrafish, various rodents, cats and monkeys. 
As variable as the species is the basis of the model: there are genetic (idiopathic) 
epilepsy models, and acquired (symptomatic) epilepsy models such as irradiation-
induced models, electrical stimulation-induced models as well as chemically-induced 
models etc. These result in development of status epilepticus (SE), chronic seizures or 
acute and induced seizure activities in the animals (Pitkanen, 2006).  
In this study, the focus lies on TLE. The three most commonly used chronic in vivo 
models for TLE in rodents are i) the kindling model, ii) the pilocarpine model and iii) 
the kainate (KA) model. Briefly, i) electrical kindling is usually done in rats. The 
animals receive a set of repetitive, short, sub-convulsive electrical stimuli in the 
hippocampus or the amygdala. This is repeated over several days until the seizure-
threshold drops and the stimulations evoke seizures in the animals without strong 
morphological changes. This “kindled state” remains for the rest of the life of the 
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animals despite that no apparent changes occur. The animals may also have 
spontaneous seizures, after multiple days of triggering kindled seizures (Racine et al., 
1975, McIntyre, 2006). However, this model is labour-intensive and does not go along 
with morphological changes, hence, it does not reflect the situation in human TLE 
patients very well. The absence of morphological changes in the hippocampus is also 
a weak point when one wants to study TLE with HS. 
ii) The most commonly used chemically induced models of TLE are the pilocarpine 
and the KA model. TLE often occurs after an ‘initial precipitating incident’ which leads 
to the development of recurrant seizures. Such incidents include febrile seizures, 
trauma or SE. Both, pilocarpine and KA are convulsants and induce SE. Pilocarpine is 
an agonist of muscarinic acetylcholine receptors. When injected systemically in 
rodents, it induces acute seizures which lead to SE and later to chronic, 
spontaneously recurrent seizures and bilateral neuronal cell loss. As in patients which 
develop TLE after febrile seizures, the onset of chronic spontaneous seizures occurs 
only after a seizure free, latent period. However, the cell loss is severe and not 
restricted to the hippocampus but affects also other limbic regions and neocortical 
areas of both hemispheres. Besides, in the pilocarpine model, the animals develop 
only low seizure frequencies from 1 per day to 1 per month (Cavalheiro, 2006). This 
makes it hard to study e.g. drug effects on seizure development. Other problems are 
the high mortality due to the SE after injection of pilocarpine and that some individual 
animals do not respond and develop seizures at all. 
iii) KA is an agonist of the kainate receptor, a glutamate receptor subtype. Depending 
on the route by which KA is administered, different subtypes of the KA model become 
manifest. If administered systemically, in a single, large dose it leads to a similar 
outcome as in the pilocarpine model with an induced SE followed by a latent period 
which is succeeded by a chronic phase; all going along with neuronal degeneration. 
In contrast to the pilocarpine model, the bilateral morphological changes are mainly 
found in the hippocampal formation and resemble strongly those found in TLE 
patients. The animals display spontaneouse nonconvulsive seizures, prolonged 
clusters of convulsive seizures, and can even develop spontaneous SE. In rats, 
seizures occur in frequencies between 0.1 – 0.6 per hour and last for an average of 1 
to 3 minutes. However, comparable to the pilocarpine model, many animals die from 
the initial SE or, they do not experience SE at all, hence do not develop epilepsy 
(Dudek, 2006).  
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More recently it was established to inject KA intracranially e.g. into the hippocampus 
which does not cause as much damage as the systemic administration and leads to 
more reliable and reproducible results (Bouilleret et al., 1999, Dudek, 2006).  
3.1.4.1 Kainic acid mouse model of temporal lobe epilepsy 
As mentioned above, a mouse model of TLE with HS has been developed using 
unilateral intrahippocampal KA injection. This model can overcome the major 
disadvantages of the kindling model and the systemic pilocarpine and KA models (e.g. 
generalised seizures, bilateral cell damage, morphological changes in other brain 
regions, low seizure frequency).  
Intracranial injection of a small dose of KA into the dorsal hippocampus induces non-
convulsive SE that lasts for several hours. EEG recordings show synchronised, 
rhythmic, discharges in the ipsilateral hippocampus and cortex as well as 
contralaterally (Figure 3.2 A, B). KA injection initiates a slow, but progressive 
neurodegeneration which persists long after the drug has been cleared. Local lesions 
of the CA1 area, especially around the injection tract can be found at 24 h post 
injection. In the hilus and parts of the CA3 regions (also called CA3c) neuronal cell 
loss can be observed (Bouilleret et al., 1999, Riban et al., 2002). 
After the SE the mice enter a latent phase which lasts for about 2 weeks. During this 
time, neurodegeneration of the ipsilateral CA1 and CA3c region as well as the hilus 
progresses, a large number of pyknotic cells can be seen. The granule cell layer of the 
dentate gyrus enlarges, the granule cells disperse (Bouilleret et al., 1999). EEG 
recordings in the ipsilateral side reveal a disappearance of normally occurring theta 
rhythm which gets replaced by a low voltage background activity with sporadic, 
isolated spike-and-waves (Figure 3.2 C, D). The contralateral side remains unchanged 
or with only minor alterations of theta activities (Riban et al., 2002, Arabadzisz et al., 
2005). 
Following the latent phase, mice begin to have frequent, recurring, spontaneous 
seizures. This marks the onset of the chronic phase which remains for the rest of their 
life. It is accompanied by further neurodegeneration which leads to a profound 
atrophy of the hippocampus (Bouilleret et al., 2000, Knuesel et al., 2001). EEG 
recordings show high voltage sharp waves lasting 4 to 10 s which are also seen in the 
contralateral hippocampus as well as typical hippocampal paroxysmal discharges 
lasting for 20 s or more (Figure 3.2 E, F). These are not seen contralaterally. Their 
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occurrence is highly variable within the recordings of a given animal but ranges from 
once or more every minute to once per hour or more (Riban et al., 2002, Arabadzisz 
et al., 2005). Morphologically the chronic phase is characterised by a complete 
degeneration of CA1 and CA3c pyramidal cells, extensive neuronal cell loss in the hilus 
a marked hypertrophy of the dentate gyrus with granule cells dispersed in a large part 
of the hippocampus (Figure 3.3). Additionally, mossy fibre sprouting in the 
supragranular molecular layer of the ipsilateral dentate gyrus and some of the 
contralateral was observed (Bouilleret et al., 1999).  
The typical pharmacoresistance which makes treatment of patients with TLE often 
impossible is also a hallmark of this model (Riban et al., 2002, Gouder et al., 2003). 
This makes it a valuable tool to study the mechanisms of refractoriness to AEDs and 
to use it to find new approaches for treatments. To achieve this, mice can be 
chronically implanted with electrodes for EEG recordings. Thus, the seizure frequency 
can be surveyed under control conditions as well as conditions where animlas recive 
treatments. To study mechanisms of epileptogenesis, seizure suppression or drug 
resistance it is possible to use mice of various genotypes and with mutations in this 
model and to apply various compounds to see how they effect seizures (Riban et al., 
2002, Gouder et al., 2003, Gouder et al., 2004, Fedele et al., 2005). With this kind of 
an approach new insights into the various aspects of epilepsy and its treatment can 
be obtained. 
Figure 3.2: Typical EEG recordings of KA treated mice. Upper traces: ipsilateral 
recordings with bipolar intrahippocampal electrodes; lower traces: ipsilateral recordings with 
monopolar intracortical electrodes. A: saline-treated mouse with normal theta activity. B: KA 
treated mouse during status epilepticus with continuous spikes or spikes and waves. C and D: 
Recordings during latent phase. C: background activity (left part of trace) and low voltage 
spikes, isolated or in groups. Enlargement shows propagation to the cortex which occurs 
sometimes. D: Bursts of high frequency activity (arrows) which occurs only at the end of the 
latent phase. E and F: Recordings during chronic phase. E: sharp waves. F: Hippocampal 
paroxysmal discharge, the typical seizure with  high voltage sharp waves followed by higher 
frequency, low voltage rhythmic activity. Adapted from (Riban et al., 2002)  
Figure 3.3: Nissl staining of mouse hippocampus cytoarchitecture after unilateral 
intrahippocampal injection of KA. Contralateral: non-injected hippocampus displaying the 
normal morphology of the hippocampal formation. Ipsilateral: KA-treated side. Neuronal loss 
in hilus, CA1 and  parts of CA3 (CA3c). Strong dispersion of dentate gyrus (DG) granule cells. 
Scale bar = 200 µm. 
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3.2 ABC transporters and the blood-brain barrier 
3.2.1 Blood-CSF and Blood-brain barrier 
The brain has to be strongly protected against toxic agents and is thus shielded from 
the rest of the body by two barrier systems: the blood-brain barrier (BBB) and the 
blood-cerebrospinal fluid barrier (BCSFB). Their function is to protect the brain and 
cerebrospinal fluid (CSF) from toxic agents or antigens and at the same time ensure 
proper supply of the necessary nutrients or passage of hormones and growth factors. 
Basically they maintain the chemical composition of the neuronal “milieu” which is 
necessary for proper functioning of the brain. In many diseases, BBB breakdown is a 
major contributing factor e.g. in multiple sclerosis, brain tumour or HIV-associated 
dementia. Changes in BBB structure and composition have also been found in 
Alzheimer’s or Parkinson’s disease (Zlokovic, 2008). 
The BCSFB is found in the ventricles, in a structure called choroid plexus (CP) which is 
responsible for the generation of the CSF. Each of the 4 ventricles has a CP consisting 
of a layer of epithelial cells which form villi, arranged around blood vessels on their 
basolateral side. Their apical side with a brush border membrane is facing the lumen 
of the ventricle. The epithelial cell layer is interconnected with tight junctions (TJ) 
which form the actual barrier. CSF is generated by filtering plasma from the blood 
through the epithelium. The process is driven by an osmotic gradient which is 
established by actively transporting ions into the ventricles. Water follows the 
gradient through pores formed by aquaporins in the membranes. Besides the ion-
transporters, the CP is also equipped with a machinery to remove metabolic waste or 
xenobiotics from the CSF (Strazielle and Ghersi-Egea, 2000). 
The BBB is built by the brain microvessel endothelial cells of the neurovascular 
system. With an estimated total length of more than 600 km and surface area of 
around 20 m2, the capillary network in the brain forming the BBB is larger than the 
BCSFB and therefore potentially more important. Similar to the BCSFB, the actual 
barrier is generated by TJs that seal neighbouring endothelial cells together, hence, 
restricting the paracellular passage of molecules. TJs are complex structures 
consisting of a multitude of proteins such as occludin, several claudins, zonula 
occludens-1 (ZO-1), ZO-2, cadherins etc. These, or their adapter molecules, which 
link the TJ to the cytoskeleton, are often affected during chronic disease which may  
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Figure 3.4: Schematic representation and electron micrograph of the BBB. A: 
Schematic drawing of the BBB (Soontornmalai, 2006). Endothelial cells and pericytes are 
separated by a basal lamina. Astrocytic endfeet sheath the microvessel. B: Electron 
micrograph the cross section of a microvessel and surrounding brain tissue. Endothelial cell 
with nucleus and tight junctions between adjacent cells. Pericyte visible on the lower right 
hand side; scale bar 500 nm (picture kindly provided by C. Petitjean). C: close up of a tight 
junction (J) formed by two endothelial cells (End) (Alan Peters, 1991). The part where the 
membranes come closely together is called zonula occludens (ZO). The astrocytic endfeet (As) 
are separated from the endothelial cells by the basal lamina (B). 
 
lead to BBB leakage. The endothelial cells are surrounded by a basal lamina which 
separates them from their neighbouring cells, the pericytes and astrocytic endfeet 
(Figure 3.4). It is thought that the endothelial cells, the pericytes and astrocytes 
cooperate to build and maintain the basal lamina. The possible role of pericytes and 
astrocytic endfeet in the barrier function is still unclear. 
The main barrier function is established by an extensive transport system regulating 
the transcellular passage of molecules. In general, 5 categories can be distinguished: 
i) carrier-mediated transport, ii) ion transport, iii) active efflux transport, iv) receptor-
mediated transport and v) caveolae-mediated transport (summarised in Figure 3.5). 
In brief, i) carriers selectively facilitate diffusion of nutrients such as sugars, amino 
acids, nucleosides or vitamins. ii) Ion transporters are mainly ATP-driven pumps such 
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as the Na+,K+-ATPase which regulate the influx and efflux of ions to maintain 
appropriate concentration gradients. These gradients are required to drive e.g. Na+ 
dependent transport. iii) active efflux is mainly initiated at the luminal membrane via 
ATP driven ABC transporters (see further down). iv) Transport of large proteins occurs 
mainly via receptor-mediated transport systems like the leptin BBB receptor. This 
system has also been targeted in pharmacological research for drug delivery via a 
strategy known as Trojan horses: agents are coupled to a monoclonal antibody 
against one of the BBB receptors (e.g. insulin). The antibodies act as surrogate 
ligands and can be used to shuttle the conjugated agent across the BBB via clathrin-
dependent internalisation of vesicles containing the receptor. v) The caveolae control 
transcytosis in sphingolipid-rich microdomains (lipid rafts) of the BBB containing 
caveolin-1. The caveolar membranes contain specific receptors. Clathrin-independent 
endocytosis of these receptors is raft-dependent (Zlokovic, 2008). 
Another basis for the barrier function is via metabolising enzymes. Endothelial cells 
express a large number of enzymes, including peptidases, esterases or drug-
metabolising enzymes like epoxide hydrolases (Ghersi-Egea et al., 1994, Zolnerciks et 
al., 2007). These can modify molecules, which could otherwise bypass the physical 
barrier (Zolnerciks et al., 2007). Therefore they contribute to regulate the inner milieu 
of the brain. 
3.2.2 ABC transporters  
ATP-binding cassette transporters (ABC transporter) represent a protein superfamily, 
which is one of the largest, and most ancient families with representatives in all 
kingdoms from bacteria to animals. ABC transporters are energy-dependent integral 
membrane proteins which can carry a variety of diverse substrates across lipid 
bilayers by hydrolysing ATP (Hollenstein et al., 2007). Proteins are classified as ABC 
transporters based on the sequence and organisation. The basic domain organisation 
of ABC transporters consist of two transmembrane domains (TMDs), providing a 
passageway for the cargo, and two conserved cytoplasmic ATP-binding (and 
hydrolysing) domain(s), known as nucleotide-binding domains (NBDs). The NBDs are 
the motor domains of the transporters and consist of several conserved sequence 
motifs. The most important ones are the ‘P-loop’ or ‘Walker-A’ motif which binds the 
nucleotide; the ‘LSGGQ’ motif, also known as ‘C-loop’ or ‘ABC signature motif’ which 
contacts the nucleotide in the ATP-bound state; the  ‘Walker-B’  motif that provides a 
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Figure 3.5: Simplified molecular atlas of the BBB: A: Carrier-mediated transporters and 
their localisation on the luminal (blood) of the abluminal (brain-)side of the endothelial cells. 
Directions of transport are indicated with arrows. B: Active efflux transporters which are 
energy dependent. Direction of transport is indicated with arrows. Adapted from (Zlokovic, 
2008). 
 
conserved glutamate residue important in ATP hydrolysis and a few more involved in 
subdomain interaction and the catalytic reaction (Hollenstein et al., 2007). Unlike the 
NBDs, the membrane spanning TMDs vary in primary sequence, length and 
architecture. Also the number of transmembrane (TM) helices varies between 
subfamilies. The two main subtypes are the ABC importers and the ABC exporters. 
ABC importers are present only in prokaryotes. In bacteria, exporters consist of two 
‘half transporters’, each consisting of a TMD fused to a NBD. These form homo- or 
heterodimers to generate the functional unit. Many eukaryotic ABC exporters on the 
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other side are expressed with all four functional domains in one polypeptide chain 
(Hollenstein et al., 2007).  
So far only crystal structures of prokaryotic ABC transporters have been solved, 
however, due to the strong conservation across species, these reveal possible 
mechanisms which apply to eukaryotic proteins as well. 
3.2.2.1 ABCB1 and ABCC1 
A subset of ABC transporters have been linked to transport of drugs and drug 
resistance. Among the mammalian ones a few have been demonstrated to have a 
well defined role in the transport of clinically relevant drugs. Hence, they are called 
multidrug transporters. The most important ones belong to the ABCB and ABCC, as 
well as the ABCG (BCRP or ABCG2) subfamily of ABC transporters. 
Structure and function of ABCB1 
The multidrug resistance protein 1 (ABCB1, also known as MDR1 or P-gp) of the ABCB 
subfamily was the first drug efflux pump to be discovered (Juliano and Ling, 1976). It 
consists of two similar halves, each containing an intracellular NBD and 6 putative TM 
segments (Figure 3.6). It is possibly the best studied ABC efflux transporter to date. 
Among many other substances, many anticancer drugs have been shown to be 
substrates of ABCB1. It was first identified due to its overexpression in cell lines, 
resistant to such cytotoxic drugs. There are a few common characteristics of 
multidrug transporter substrates. They are usually planar, heterocyclic, lipophilic 
organic compounds with a molecular mass ranging from less than 200 Da to about 
800 Da; they often contain aromatic groups. The most efficiently transported 
molecules are uncharged or weakly cationic (Schinkel and Jonker, 2003, Higgins, 
2007).  
Crystal structure analysis mimicking the ATP bound state of the homodimeric 
Staphylococcus aureus multidrug transporter Sav1866, which is structurally related to 
ABCB1, revealed an outward facing conformation with the two NBDs in close contact 
and the two TMDs forming a central cavity (Figure 3.6 B, C). In this state the 
substrate could be released into the extracellular space. Hence, the simplest transport 
mechanism would involve two states: an inward-facing conformation with the 
substrate binding site accessible from the cytoplasm and an outward-facing 
conformation with an extrusion pocket exposed to the external medium. ATP 
hydrolysis is expected to return the transporter to an inward-facing conformation. 
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Figure 3.6: Structure of the ABC transporter families ABCB and ABCC. A: Two-
dimensional structural and topological models of brain multidrug transporters with 
transmembrane segments, glycosylation sites (GS) and NBDs (ATP). Compared to the ABCB1 
and some members of the ABCC family, ABCC1, 2, 3 and 6 have an additional amino (N)-
terminal domain, with five transmembrane segments. Except for the location of their 
glycosylation sites, their structure is similar to that of ABCB1. (Loscher and Potschka, 2005) B: 
Crystal structure analysis derived representation of the backbone of the homodimeric ABCB1 
homologue Sav1866 in ribbon representation, with the subunits coloured yellow and turquoise. 
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What was new from this structure analysis was the insight that the TMDs of Sav1866 
from one subunit of the homodimer reach across and contact primarily the NBD of the 
opposite subunit and vice versa. Such swapping had not been anticipated for ABC 
exporters, but was not inconsistent with the available biochemical or genetic data. 
However, it contrasted the earlier idea of a side side-by-side arrangement of the two 
halves (Dawson and Locher, 2006).  
From this and other recent crystal structures of full transporters it was postulated that 
ATP binding and hydrolysis by the NBDs drives inward-facing or outward-facing 
conformations of the TMDs. The key to effective unidirectional transport seems to be 
the ATP-driven ‘closing’ of the NBDs. Thereby the distance between the coupling 
helices decreases which in turn triggers a flipping of the TMDs from an outward to an 
inward-facing conformation. ABC exporters my now extrude bound drugs to the 
environment. Upon releasing ADP and inorganic phosphate, the transporter may flip 
back to an inward-facing conformation and exporters may recruit new substrates into 
high affinity binding sites. This modus operandi seems to be common for all types of 
ABC transporters (Hollenstein et al., 2007). 
 
 
 
 
 
 
 
a: Bound ADP is in ball-and-stick representation. The view reveals the membrane-embedded 
'wings' of the protein with the grey box depicting the probable location of the lipid bilayer  
based on  hydrophobicity of the protein  surface. right:  90° rotation compared to left  
side. The TM helices of one subunit (turquoise) are numbered. ICL, intracellular loops 
(between transmembrane helices); ECL, extracellular loops (between transmembrane helices); 
Bb: Views from the extracellular side into the transporter cavity at two levels. The 
transmembrane helices are numbered and the cavity is shown as a grey surface. Left: at the 
level of the inner leaflet. Right: at the level of the outer leaflet. Note that owing to helix 
bending, different subsets of helices line the cavity (Dawson and Locher, 2006). 
C: Schematic of Sav1866 in the observed, outward-facing conformation. The cartoon 
emphasises the domain swapping and subunit twisting. Arrows indicate the release of bound 
drug into the extracellular space (Dawson and Locher, 2006). 
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ABCB1 is expressed in the intestine as well as in various barriers in the body such as 
the blood-testis barrier, the blood-nerve barrier or the foetal-maternal barrier in the 
placenta and also in the BBB. It seems obvious that ABCB1 has evolved to protect the 
vulnerable parts of the body from damaging effects of xenotoxins which were taken 
up with the food or generated by pathogenic organisms in the intestine (Schinkel and 
Jonker, 2003). ABCB1 is also expressed in the kidney where its function is less clear. 
It is abundant in the apical (luminal) membrane of proximal tubules. One would 
expect it to have excretory function there despite this has not been proven to date 
(Schinkel and Jonker, 2003). In rodents, ABCB1 has two orthologues: Abcb1a and 
Abcb1b. They are expressed with complementary tissue distribution. In the rodent 
brain, Abcb1 has been shown to localise at the apical, luminal membrane of 
microvascular endothelial cells (Soontornmalai et al., 2006, Roberts et al., 2008). 
Data about the distribution in the BCSFB is conflicting, nevertheless, data from our 
group as well as others suggests that Abcb1 is not present in the CP ependyma of 
rodents (Soontornmalai et al., 2006, Roberts et al., 2008). As mentioned above, there 
are studies which found that the transporter is overexpressed in brain from patients 
with intractable TLE (Dombrowski et al., 2001, Sisodiya et al., 2002, Aronica et al., 
2004) or in brains from rodent models of TLE (Rizzi et al., 2002, Volk et al., 2004). 
The ABCC family; structure and function 
The multidrug resistance-associated protein 1 (MRP1) or ABCC1 was the first member 
of the ABCC family which was cloned in 1992 from drug-selected human lung cancer 
cells (Cole et al., 1992). The cells from which it was cloned showed similar resistance 
properties as were known from cells expressing ABCB1. Nevertheless, analysis of the 
computer-predicted topology of the membrane spanning domains (MSDs) revealed 
unusual properties for an ABC transporter. Also the two putative NBDs, which are 
highly conserved in most ABC transporters, were relatively divergent and resembled 
more to those of a chloride channel (CFTR) rather than a drug pump. Though, gene 
transfer experiments revealed that ABCC1 could confer resistance to drugs from 
several natural drug product families including Vinca alkaloids. It was also found to 
confer resistance to heavy metal oxyanions such as sodium arsenate where ABCB1 
has no effect. This lead to the idea to compare it to the sequence of the protozoan 
Leishmania tarentolae ABC transporter ltpgpA, which had been shown to increase 
resistance to arsenicals. The two transporters proved to be homologues of each 
other, rather than of ABCB1. Since then it has become obvious that the ABCC 
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subfamily is so far the largest. It comprises 10 MRPs (ABCC1-6 and ABCC10-13) as 
well as the CFTR (ABCC7) and the sulfonylurea receptors SUR1 (ABCC8) and SUR2A/B 
(ABCC9) (Deeley et al., 2006).  
Based on the predicted topology, the ABCC proteins fall into two groups: the short 
and the long ABCC proteins. ABCC4, 5, 7, 11 and 13 have a “typical” ABC transporter 
structure with two MSDs, each with 6 TM helices, while the others (ABCC1, 2, 3, 6, 8, 
9, 10 and 12) have an additional n-terminal region which is poorly conserved but 
contains 4 – 6 TM helices (Figure 3.6 A). Within the family, the NBDs are highly 
conserved and contain all functional motifs as described above. The additional MSD of 
ABCC1 has only recently been ascribed a function in retention in and recycling to the 
plasma membrane (Deeley et al., 2006).  
ABCC1 functions mainly as a (co-)transporter of amphipathic organic anions. It can 
transport hydrophobic compounds that are conjugated to glutathione (GSH), 
glucuronic acid or to sulphate and the export has been shown to rely on the presence 
of GSH in the cytoplasm. It is therefore likely that it exports drugs such as vincristine 
by co-transport with reduced GSH (Schinkel and Jonker, 2003). 
The protein is widely expressed in the body with high levels in lungs, testis, kidneys, 
skeletal and cardiac muscles and the placenta but seems absent form the adult 
human liver (Deeley et al., 2006). ABCC1 is predominantly expressed on the 
basolateral side of epithelial cells and its substrates are therefore transported to the 
basolateral side of the epithelia. It contributes to the protection of tissues witch are 
shielded from blood-borne toxins by epithelia that have the basolateral membrane 
facing the blood circulation as is also the case in the CP (Deeley et al., 2006). 
In the brain the findings are conflicting. However, Abcc1 the rodent orthologues of 
ABCC1 was found at basolateral membranes of BBB endothelial cells by our group and 
others (Soontornmalai et al., 2006, Roberts et al., 2008). Nevertheless, it’s function 
there remains elusive and proof for expression at the basolateral membrane of 
healthy human microvascular endothelial cells is lacking despite that it was found in 
brain tissue from patients with TLE (Aronica et al., 2004). 
Its presence in the CP on the other hand has been well established. Abcc1 is localised 
on the basolateral membrane of ependymal cells where it acts to protect the brain 
from toxins (Lee et al., 2001, Soontornmalai et al., 2006, Gazzin et al., 2008, Roberts 
et al., 2008).  
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3.2.3 Models of the BBB 
To date, quite a few BBB models have been established. Hence the BBB is studied 
using in vivo or in vitro models. Depending on the focus of investigations, be it to 
investigate the cellular and molecular composition of the BBB, or the permeability, the 
properties of the model systems are adjusted. Nontheless, the most important feature 
is the regulated, specific permeability of the barrier.  
Studies in animals include carotid artery injection, in situ brain perfusion or 
intracerebral microdialysis as reviewed in (Nicolazzo et al., 2006). All three techniques 
are used to assess permeability, especially uptake through the BBB for certain 
compounds such as drugs. They will be described briefly in the following. The carotid 
artery single injection, also known as brain uptake index (BUI) can be used in high-
throughput settings as it is fast and easy. In this assay a small volume of buffered 
solutions containing the compound of interest and a radiolabelled diffusible reference 
compound is rapidly injected into the carotid artery. The animal is decapitated 5 to 15 
s after injection and the brain and solute are analysed to calculate the BUI. The 
disadvantage is that the capillary transit time is very short and that the drug might 
back-diffuse from the brain to the blood or that it might be metabolised. However, it 
is suited to evaluate a large number of drugs in a short time (Nicolazzo et al., 2006). 
In situ brain perfusion, an extension of the carotid artery single injection, has been 
used since more than 50 years and the technique has been simplified through the 
years. In this method, the animal (mostly a rat) is anaesthetised and the perfusion 
catheter is placed in the external carotid artery and the other ipsilateral arteries are 
cut. Then a compound of interest and a reference compound are perfused for a 
certain time. Following the perfusion the animal is decapitated and the compound 
concentration is determined. The problem with this technique, and also with the 
single injection technique, is that a compound which is not within the capillary can be 
either in the brain parenchyma (transcytosis), as is assumed, or can be caught in the 
capillary, either bound to  the endothelia or inside the endothelial cells (endocytosis) 
(Nicolazzo et al., 2006). Thus, results have to be evaluated with this caveat in mind. 
Intracerebral microdialysis involves direct sampling of interstitial fluid. A dialysis fibre 
is implanted into the brain; hence, the concentration of a compound that has 
permeated into the brain upon oral, intravenous or subcutaneous administration can 
be monitored over time. The microdialysis probe consists of a semipermeable 
membrane and is perfused with a physiological solution so small compounds traverse 
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the membrane in a concentration driven manner. The major advantage of this 
method is that not many animals need to be killed to assess the pharmacokinetic 
profiles of compounds in the brain. It is also quite accurate as both, plasma and brain 
levels of the compound can be determined over time and the probe can be placed in 
any region of the brain. This may be useful if one wants to assess the specificity of a 
targeted compound. However, the disadvantages are that only very low 
concentrations of compound may be present in the dialysate which may be hard to 
measure.  Also, by insertion of the dialysis probe, a chronic disruption of the BBB 
could result (Nicolazzo et al., 2006). 
However, the easiest way to study the role of a certain protein is to investigate its 
role in knock-out (ko) models. In this regard, a few mouse strains, lacking certain 
transporters which are thought to play a role in the BBB permeability, have been 
generated. These can be used in combination with one of the methods mentioned 
above or in an animal model for a disease or disorder such as the KA induced model 
for TLE which was described above. 
In contrast to the in vivo models, in vitro models can more easily be used for high-
throughput screenings. The era of in vitro studies of the BBB was opened more than 
30 years ago in 1973, when Joó and co-workers (Joo and Karnushina, 1973) 
successfully isolated viable microvessels. Subsequent experiments provided important 
data on brain endothelial receptors, transporters and signalling mechanisms. Five 
years later, in 1978, the first observations on brain microvessel endothelial cells in 
culture were published by Panula and co-workers (for review see (Deli et al., 2005). 
Since then, the simplest models are based on one cell type. Still commonly used are 
primary microvessel endothelial cells isolated from cow, pig, rat or mouse brains or 
even from human brain specimens. As the extracellular matrix is crucial, also in 
culturing brain endothelial cells, they are grown on collagen coated substrates which 
leads to a higher trans-endothelial electrical resistance (TEER). The TEER varies 
between species from which the cells were isolated and ranges for example in bovine 
brain endothelial cells from an average of 500 - 800 Ω*cm2 (Deli et al., 2005). First 
insights into the molecular composition and functional properties of brain endothelial 
cells were obtained by growing them in culture dishes. To assess their permeability 
they are often grown on filter inserts (Figure 3.7 A) to obtain a two-compartment 
system  (Joo,  1992).  These  primary  or  low passage  microvessel  endothelial  cells  
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Figure 3.7: Schemes of in vitro models 
of the BBB. A and B are static systems. A: 
tight monolayer of only one cell type (e.g. 
endothelial cells) dividing the system into two 
compartments: an apical (abluminal) and a 
basolateral (luminal) compartment. B: co-
culture two compartment system. Top: non-
contact method with co-cultured cells (e.g. 
astrocytes) growing on the bottom of the 
multiwell plate. Low: contact method with co-
cultured cells growing on the underside of the filter. C: Dynamic system with endothelial cells 
monolayer growing on the inside of a porous hollow fibre capillary which is perfused with 
culture medium to provide shear stress. Glial cells grow in several layers on the outside of the 
capillary. The whole system is inside a sealed chamber (extraluminal space). 
 
provide closest resemblance to the in vivo BBB. However, the monocultures can only 
be cultivated for a limited number of passages before they lose their characteristic 
phenotype including the high TEER. By co-culturing astrocytes, which have also been 
shown to induce the development of TJ in brain endothelial cells, this de-
differentiation can partially be prevented (Figure 3.7 B). Other neighbouring cells of 
the brain microvasculature have also been used in co-cultures. Among these are 
pericytes or even neurons (Deli et al., 2005). However, one has to keep in mind that 
for some applications the presence of other cell types might be a hindrance rather 
than an advantage as it might not always be possible to allocate an observed effect to 
one cell type and its components. 
All the models mentioned above are static. Hence, they might not display the real 
situation which underlies also physical shear stress evoked by the blood flow. This 
lead the group around Janigro to develop a new, dynamic model which has a 3-
dimensional tube structure with a continuous flow of culture medium, mimicking the 
physiological shear stress in blood vessels. While endothelial cells are grown in a 
monolayer inside the fibre capillary in a sealed chamber the medium can be pumped 
through the capillary in a continuous, pulsing flow, mimicking the blood flow in brain 
capillaries. On the outside of the porous capillary, glial cells, which are present around 
brain microvessels, are grown. These form several cell layers (Figure 3.7 C). This 
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model leads to very high TEER as found in vivo and seems well suitable to study 
transport properties (Stanness et al., 1997, Stanness et al., 1999).  
In general, to appropriately mimic the BBB, there are some basic characteristics which 
a model must possess. These are: a) restricted paracellular transport which can be 
measured by the TEER. A minimal TEER of 150 – 200 Ω*cm2 was shown to be 
sufficient to assess drug permeability in vitro. However, that of the in vivo BBB is 
more than 2 kΩ*cm2. b) Brain endothelial cell characteristics including morphology 
(monolayer formation) and expression of the proper enzymes and BBB markers. c) 
Functional expression of BBB-specific transport machineries e.g. for nutrient transfer, 
efflux pumps etc. d) In vivo-like modulation properties such as alteration of 
permeability by interleukins, glial factors etc and e) Practicality of the system, 
including availability, convenience, predictability and reproducibility (Nicolazzo et al., 
2006). 
Primary cultures have disadvantages. They are expensive and time-consuming. 
Additionally, it is difficult to ensure purity and homogeneity of the cultures, since they 
are easily overgrown by contaminating cells such as pericytes (Deli et al., 2005). It is 
also difficult to genetically modify them by transfection due to their short life span. 
To overcome some of these problems immortalised brain endothelial cells have been 
generated. However, none of the more than 20 cell lines can fulfil all the criteria 
which include the reproducibility and sufficient tightness due to incomplete formation 
of TJs which results in “leaky” barriers (Deli et al., 2005, Nicolazzo et al., 2006). 
Due to the insufficient barrier properties of immortalised brain endothelial cell lines, it 
has become custom to use non-cerebral peripheral epithelial cell lines instead. One 
such line is the Madin-Darby canine kidney (MDCK) cell line. These cells are easy to 
grow and can be genetically modified by transfection. They are polar and upon 
transfection with a cDNA encoding a transporter such as ABCB1 will express it on the 
appropriate membrane (Pastan et al., 1988). They have also been shown to have 
high absorptive transport for CNS-positive drugs and low absorptive transport for 
CNS-negative drugs. Hence, they seem to be a suitable model for BBB permeation 
(Wang et al., 2005, Nicolazzo et al., 2006). On the other hand, MDCK cells are more 
cuboidal than brain endothelial cells and therefore have a relatively larger transverse 
area of intercellular TJs than brain endothelial cells. Consequently, paracellular 
transport may be overestimated with these cells. One also has to keep in mind that 
the expression pattern of transporters is not exactly the same in MDCK cells as in 
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brain endothelial cells. Caco-2 cells have also been used in BBB models. Like MDCK 
cells they are epithelial cells and have different morphological characteristics to brain 
endothelial cells (Nicolazzo et al., 2006). Common for all cell lines is that they are 
frequently used as BBB model when grown to tight monolayers in a two-compartment 
filter-insert system as shown in Figure 3.7 A.  
3.2.4 Transport of AEDs by ABC transporters 
So far, several groups have used transfected MDCK cells or other epithelial cell lines 
to study AED transport by recombinant ABC transporters. To date, most studies were 
performed in cells which constitutively express the recombinant proteins and non-
transfected cells were used as background controls (Evers et al., 2000a, Evers et al., 
2000b). Additionally, if one wants to study the role of an efflux transporter it is also 
possible to use cancer cell lines that are resitant to drugs through the expression of a 
specific transporter. These can be used in cytotoxicity assays and in uptake assays. In 
the cytotoxicity assay a substrate can be determined by addition of the compound of 
interest to the cells together with a cytotoxic agent to which the cells are resitant 
(e.g. vinblastine in case of ABCB1 expression). If the cells lose their resistance, the 
compound of interest is considered a substrate which is transported in a competitive 
manner. A similar phenomenon is tested in the uptake assay. Here cells are treated 
with the compound of interest during uptake of a radiolabled substrate. If the uptake 
is reduced, the compound of interest is considered a substrate as well (Rivers et al., 
2008). 
Despite, or because of the use of various in vitro and in vivo systems, transport data 
for ABC transporters are conflicting. Compounds which are good substrates such as 
vinblastine or vincristine could be shown to be transported with high transport ratios 
(TRs). These have since been used as positive controls in transport studies (Paul et 
al., 1996, Mao et al., 2000). Especially data about the transport of AEDs by the ABC 
transporters ABCB1 and ABCC1 are conflicting and for some drugs rather scarce. For 
others, like ABCC2, even less is known. To our knowledge only two in vitro studies on 
the transport of lamotrigine were carried out. Rivers et al. (2008) have not found it to 
be a substrate of either transporter in cytotoxicity and uptake assays whereas Luna-
Tortos et al. (2008) found it to accumulate apically after prolonged incubation in a 
concentration equilibrium system expressing ABCB1. In vivo data on lamotigine 
transport in mice using blood-serum concentrations could not prove it to be a 
substrate of Abcb1a (Sills et al., 2002). A few more studies were performed on CBZ 
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transport by ABCB1 or ABCC1, nevertheless, data is controversial. While no transport 
by Abcb1a could be measured in mice in vivo by Owen et al. (2001a), Potschka et al. 
(2001) found it to be a substrate of both, ABCB1 and ABCC1 in a microdialysis study 
in rats. However, in subsequent cell culture studies by the same group, comparing 
transport by recombinant human and mouse proteins, this finding could not be 
verified (Baltes et al., 2006). Additionally, other groups could not find in vitro 
evidence for CBZ to be a substrate of ABCB1 or ABCC1 either (Owen et al., 2001a, 
Rivers et al., 2008). It was criticised that weak substrates might be missed due to 
masking of transport by passive diffusion in the commonly used in vitro studies. Most 
studies have been performed in concentration gradient setups where a compound to 
be tested is added to one side of a two-chamber system, hence passive, osmoses-
driven diffusion could occur and mask active transport. To rule this out, Luna-Tortos 
et al. (2008) developed a concentration equilibrium system in which they studied 
transport of AEDs. With this they found in prolonged experimental setups that 
lamotrigine is transported by ABCB1 but CBZ is not. In case of ABCC2, a study in 
naive rats using microdialysis gave no evidence of its involvement in the entry of CBZ 
or lamotrigine into the CNS; but Abcc2 deficiency was associated with an increased 
anticonvulsant response to CBZ in kindled rats (Potschka et al., 2003). For the 
evaluation of this kind of data one has to keep in mind that there might be 
differences of substrate recognition of the transporters from different species. This is 
stressed by the finding that the AEDs phenytoin and levetiracetam were directionally 
transported by mouse but not human ABCB1, whereas CsA was transported by both 
types of ABCB1 (Baltes et al., 2006). A main caveat with all cell culture studies is the 
lack of a good baseline control. It is common practice to use non-transfected MDCK 
cells as baseline. However, these have been cultivated separately for some time and 
may have diverged, not featuring the same original characteristics any longer. MDCK 
cells have a wide range of endogenous transporters which may also contribute to 
drug transport. If the control cells do not express them to the same extent as the 
transfected cells, false positive results may be obtained or, as with passive diffusion, 
weak transport might be masked. This can partially be overcome by the use of 
inhibitors to potential endogenous transporters, however, these inhibitors are not 
always very selective and in some cases can also act as enhancers (Huisman et al., 
2002, Zimmermann et al., 2008). Thus it is important to establish a good baseline 
control. In this work, we used MDCK cells with inducible expression of recombinant 
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transporters. Hence, cells cultivated together and from the same clone were used in 
transport studies when the transporter was induced, and served as baseline control in 
the non-induced state. 
In vivo studies of AED transport have often been performed using microdialysis to 
analyse brain penetration of a certain drug. This can be tricky to analyse if the 
concentrations are low. In this study, we wanted to assess the involvement of ABC 
transporters in drug resistance by looking at the direct effect of an AED in epileptic 
mice which do or do not express the transporter of interest. 
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3.3 Aims 
What is the role of multidrug transporters of the ABCB and ABCC family in AED 
resistance in TLE? This was the question we wanted to answer with this PhD thesis. It 
is thought that multidrug transporters of the ABC superfamily are responsible for 
multidrug resistance in TLE. However, the mechanism is not yet clear. So far, it was 
established that some ABC transporters are present at the BBB or BCSFB. However, 
unambiguous proof of their involvement in drug export, resulting in sub-threshold 
concentrations in the brain and target areas, has so far not been found. Also, it is not 
clear which AEDs are substrates for any of the ABC transporters present in these 
barriers. Hence we set out to assess substrate specificity for the two ABC transporters 
ABCB1 and ABCC1 using two approaches, one in vitro and one in vivo.  
For the in vitro approach, we aimed to generate a barrier model which is better suited 
for the analysis of drug transport by a specific multidrug transporter than previously 
established models. To this end, we generated a novel BBB model, comprised of 
MDCK cells stably transfected with an inducible expression cassette containing either 
human ABCB1 or ABCC1 cDNA. The inducibility of the transporter expression should 
ensure to have a better baseline control for transport experiments than simply non-
transfected MDCK cells. The baseline of active and passive transport should be the 
same in induced and non-induced cells, therefore, induced transporter-mediated 
effects should be clearly identifiable. With this system, we expected to be able to 
unambiguously assess whether two first line AEDs, CBZ and lamotrigine, are 
substrates of either of two ABC transporters, ABCB1 or ABCC1, which have been 
shown to be expressed at the BBB. 
In the in vivo approach, we sought to test the multidrug transporter hypothesis in the 
intrahippocampal KA injection mouse model of TLE. Mice in this model had previously 
been shown to be pharmacoresistant to several AEDs (Riban et al., 2002, Gouder et 
al., 2003). We used wild type (WT) and knockout mice lacking the abcb1a gene. We 
wanted to test if the mouse ABC transporter is responsible for this drug-resistance. 
Hence, the effect of the AED CBZ was assessed in this model by analysing seizure 
frequency and duration before and after injection of the drug or vehicle in WT and in 
transporter-deficient mice. If Abcb1a were responsible for drug resistance in this 
model, a marked reduction of seizures in the transporter-deficient mice compared to 
WT would be expected. Previous experiments have shown that, under physiological 
conditions, the ABC transporters Abcb1a and Abcc1 do not influence the CBZ-induced 
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sedation and thus, do not seem to mediate lowered brain penetration of small 
amounts of CBZ in healthy mice (Soontornmalai, 2006). Thus, we wanted to assess 
whether the role of the ABC transporter is different in epileptic mice and with higher 
doses of CBZ than with lower doses in healthy mice. 
By combining results from both approaches we aimed to assess the validity of the 
transporter hypothesis for AED resistance. 
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4 Results: in vitro study 
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4.1 Abstract 
Pharmacoresistance in neurological disorders such as epilepsy might be due to 
insufficient drug levels in the brain through overexpression of multidrug exporters of 
the ATP-binding cassette (ABC) protein superfamily at the blood-brain barrier (BBB). 
Determination of the substrate specificity of ABC transporters for antiepileptic drugs 
(AED) will be crucial to understand their brain distribution under normal and 
pathological conditions and for future development of drugs with improved brain 
penetration. Here, we characterised a novel in vitro BBB model to assess the 
substrate specificity of the human ABC transporters ABCB1 and ABCC1 for 
carbamazepine and lamotrigine, two first-line AED. We established monoclonal MDCK 
cell lines, stably transfected with inducible expression-cassettes for ABCB1 and 
ABCC1, respectively. Immunocytochemistry and immunoblot analysis revealed correct 
subcellular localisation of recombinant protein in polarised cells after doxycycline-
mediated induction of expression; formation of functional tight junctions could be 
confirmed by measuring transepithelial electrical resistance. To assess drug transport 
we measured changes in drug concentration by LC-MS/MS analysis in the basolateral 
and apical compartment of a two-compartment system, as well as intracellularly. 
Genetically identical, non-induced cells served as baseline control. The functionality 
was demonstrated using vinblastine and vincristine, substrates of ABCB1 and ABCC1 
respectively. Surprisingly, we observed that all compounds tested are transported in a 
direction-specific manner through MDCK cells, independent of the presence of 
inducible ABC transporters. This may be due to the expression of potent endogenous 
transporters. Despite the operational system, no evidence was found that 
carbamazepine or lamotrigine are substrates of either ABCB1 or ABCC1. 
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4.2 Introduction 
Epilepsy is a common neurological disorder affecting 0.5 - 1.0% of people worldwide. 
Despite the availability of several first-line antiepileptic drugs (AEDs) with different 
modes of action, including carbamazepine (CBZ), phenytoin, and lamotrigine (French 
et al., 2004, Marson et al., 2007), pharmacoresistance remains a major challenge in 
the clinical management of epilepsy, affecting a large fraction of patients with 
temporal lobe epilepsy (Stephen et al., 2001). 
The biological basis of pharmacoresistance is unclear but likely to be multifactorial 
and can arise as a consequence of epilepsy (Jandova et al., 2006), or can be pre-
existent, for example due to a modified drug target. For AEDs interacting with 
neurotransmitter receptors or ion channels, alterations in channel structure or 
accessory proteins leading to reduction of drug affinity or efficacy have been 
postulated (Ellerkmann et al., 2003, Schmidt and Loscher, 2005). Pharmacoresistance 
might also reflect impaired penetration of AEDs into the brain, due to overexpression 
of transporters of the ATP-binding cassette (ABC) superfamily at the blood-brain 
barrier (BBB). These may prevent therapeutic concentrations of AEDs in the epileptic 
focus despite adequate plasma levels (Loscher and Potschka, 2002, Sisodiya, 2003). 
Increased expression of ABC transporters in tissue from patients with drug-resistant 
epilepsy (e.g. (Dombrowski et al., 2001, Sisodiya et al., 2002) and seizure-induced 
expression in animal models (Zhang et al., 1999, Kwan et al., 2002, Volk et al., 2004) 
support this theory.  
The best characterised ABC transporters are the “multidrug resistance protein” ABCB1 
(MDR1 or P-gp; in rodents Abcb1a and Abcb1b) and “multidrug resistance-associated 
protein 1” ABCC1 (MRP1; in rodents Abcc1). ABCB1 is highly abundant in organs with 
secretary function and blood-tissue barriers like the BBB, where it resides at the 
luminal (apical) side of capillary endothelial cells (Soontornmalai et al., 2006, Roberts 
et al., 2008). ABCB1-immunoreactivity has been reported in neurons and glial cells in 
epileptic tissue (Dombrowski et al., 2001, Sisodiya et al., 2002, Aronica et al., 2004). 
It extrudes a range of structurally and functionally unrelated substances (Kwan and 
Brodie, 2005). Data for AEDs is controversial. For example, CBZ was not found to be 
an ABCB1 substrate in vitro and in Abcb1a/1b-null mice (Owen et al., 2001b, Baltes et 
al., 2006). In contrast, increased CBZ levels were found by microdialysis in rat brain 
when Abcb1 was blocked by verapamil infusion (Potschka et al., 2001). Finally, 
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directional in vitro transport of lamotrigine by ABCB1 has been described (Luna-Tortos 
et al., 2008). 
ABCC1 is highly expressed in lungs, testis, kidneys and choroid plexus (CP) (Deeley et 
al., 2006). Its distribution in brain, which might be altered by certain pathologies, is 
not yet firmly established. In addition to microvasculature, parenchymal expression in 
epileptic foci was suggested (Sisodiya et al., 2002, Aronica et al., 2004). Abcc1 was 
detected immunohistochemically basolaterally in mouse brain endothelial cells 
(Soontornmalai et al., 2006, Roberts et al., 2008). A recent study in rats found Abcc1 
predominantly expressed in the CP rather than the microvascular endothelium (Gazzin 
et al., 2008). Like ABCB1, ABCC1 has a wide substrate range, mostly organic anions, 
which are transported either when conjugated to glutathione (GSH), glucuronide or 
sulphate, or unmodified with GSH co-transport (Leslie et al., 2001). Data for AEDs as 
substrates of ABCC1 is inconclusive. While increased cerebral CBZ levels were found 
by microdialysis in rat brain when Abcc1 and Abcc2 were blocked with probenecid 
(Potschka et al., 2001), recent in vitro data argue that ABCC1 is no transporter for 
several AEDs, including CBZ and lamotrigine (Rivers et al., 2008). 
In vitro drug transport assays across a monolayer of epithelial cells overexpressing an 
ABC transporter represent a substitute for the BBB (Baltes et al., 2006). However, 
such systems are limited by potential loss of transgene expression over time, difficulty 
to assess expression levels of recombinant proteins, and lack of suitable control for 
endogenous transport mechanisms.  The aim of the present study was to establish an 
in vitro assay based on inducible expression of ABC transporters (ABCB1 or ABCC1 
and eGFP reporter) in monoclonal lines of Madin-Darby canine kidney (MDCK) cells. 
This cell line was selected for its capacity to form tight monolayers with polarised 
membrane protein distribution. Inducible expression was driven by a tetracycline-
regulated bidirectional promoter, allowing direct comparison of the drug transport 
capacity of genetically identical cells in the absence (non-induced, vehicle-treated 
cells) or presence (induced; doxycycline-treated cells) of the recombinant transporter 
to be tested. Upon morphological and functional characterisation of monoclonally 
selected cell lines, two first-line AED, CBZ and lamotrigine, were tested as potential 
substrates of ABCB1 and ABCC1.  
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4.3 Material and Methods 
4.3.1 Plasmids 
The antibiotic resistance cassette (SV40-zeocin) of the commercial vector pBudCE4.1 
(Invitrogen, Basle, Switzerland) was replaced by the β-lactamase/SV40-
neomycin/kanamycin resistance cassette (pBUDneo/kan). The gene for the reverse 
tetracycline-dependent transactivator (rtTA), derived from plasmid pUHrt 62-1 (kind 
gift from Prof. H. Bujard, ZMBH Heidelberg, Germany), was generated by PCR to 
destroy an internal 3’ XbaI site and ligated into pBUDneo/kan (KpnI/BclI) 3’ of the 
promoter for human elongation factor 1α (pBUDrtTA-XbaI). A TetO7 responder 
cassette, consisting of seven Tet-operator sequences flanked by two, bi-directionally 
pointing CMV minimal promoters and an eGFP gene from pGFPlacZ (Krestel et al., 
2001)  on one arm was cloned into pBUDrtTA-XbaI (XbaI/SpeI) resulting in plasmid 
prtTA-eGFP-TetO. The cDNA of human ABCB1 (wt haplotype C1236-G2677-C3435) 
from pGEM3Zf(-)Xba-ABCB1.1 (LGC Promochem/ATCC, Molsheim, France) was then 
cloned into  prtTA-eGFP-TetO (XbaI) resulting in prtTA-eGFP-TetO-ABCB1. 
 
 
 
 
Figure 4.1: A and B: Vector maps of the two generated plasmids indicating the main 
restriction sites used during the cloning procedure, as well as the relevant promoters and 
genes used in this study. A: Vector containing flag-tagged ABCB1 cDNA (black boxed arrow) 
and bi-directionally expressed eGFP (grey boxed arrow). B: vector containing flag-tagged 
ABCC1 cDNA (black arrow) and bi-directionally expressed eGFP (dark grey arrow). C: 
Schematic drawing of in vitro BBB model. MDCK cells build a tight monolayer on “Transwell” 
membrane inserts dividing the well in an apical and basolateral compartment.  
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Full-length human ABCC1 cDNA (non-synonymous SNP T117M, synonymous SNP 
N293N, L560L; kind gift of Prof. P. Borst, The Netherlands Cancer Institute, 
Amsterdam, The Netherlands) from pRC/RSV (Zaman et al., 1994) was cloned into 
prtTA-GFPTetO (blunt end) to result in rtTA-GFPTetO-ABCC1.  
The two plasmids were re-cloned to contain a 3’ triple flag-tag for better detection in 
immunocytochemical and immunoblot assays of ABC-transporter proteins. PCR with 
primers containing a triple flag-tag was used to amplify the 3’ end of the respective 
ABC transporter gene which was then cloned back into the plasmids (PmeI 
partial/AatII for rtTA-eGFP-TetO-ABCB1-flag; AatII/AgeI partial for rtTA-GFPTetO-
ABCC1-flag) (Figure 4.1 A and B). 
4.3.2 Generation of stably transfected MDCK cell lines 
Plasmids prtTA-eGFP-TetO-ABCB1-flag and -ABCC1-flag were linearised (PvuI) and 
MDCK cells were transfected (LGC Promochem/ATCC) using the cell line nucleofector 
kit L (for MDCK cells; Amaxa, Cologne, Germany). Cells were grown on TPP® (TPP, 
Trasadingen, Switzerland) plastic culture dishes in MEM supplemented with 10% v/v 
foetal calf serum, 1% v/v L-glutamine, 1% v/v non-essential amino acids (all from 
Gibco, Invitrogen), 1% v/v sodium pyruvate (Sigma-Aldrich, Buchs, Switzerland). 
Stable genomic integration was selected for by addition of 400 µg/mL G418 (Sigma-
Aldrich). After about 14 days, when all cells in a mock-transfected culture were dead, 
the selection was considered to be complete. G418 was always added to maintenance 
cultures but not for experimental cultures. Monoclonal cell lines containing prtTA-
GFPTetO-ABCB1-flag (thereafter referred to as MDCK-ABCB1) or prtTA-GFPTetO-
ABCC1-flag (referred to as MDCK-ABCC1) were generated by limited dilution in 
selective maintenance medium and subsequent picking of cell clones using cloning 
cylinders (Scienceware, Sigma-Aldrich). These clones were expanded and analysed by 
Western blotting and immunocytochemistry (ICC) to verify inducible expression of the 
gene with 0.5 to 1 µg/mL doxycycline hyclate (DOX) (Sigma-Aldrich) and correct 
targeting of the protein to the apical or basolateral cell surface. Monoclonal lines 
fulfilling all requirements were chosen for further experiments. The cell lines were 
used for transport experiments for up to 7 passages after transfection. 
4.3.3 Immunoblot 
Two μg of protein from cell extracts of induced (DOX-treated for 24 h) or non-induced 
(non-treated with DOX) cells were analysed using a 7.5% SDS-PAGE and subsequent 
transfer onto nitrocellulose membranes (Osmonics, EGT Chemie, Taegerig, 
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Switzerland). Membrane blocking and incubation with antibodies were done in a 5% 
w/v milk-TBST solution. Induced ABC transporters were labeled with mouse anti-
FLAG® M2 (1:5000; Sigma-Aldrich). Rabbit anti-β-actin (1:5000; Sigma-Aldrich) 
antibody was used as loading control. Horseradish peroxidase coupled goat anti-
mouse and goat anti-rabbit secondary antibodies (1:5000; Santa Cruz, Heidelberg, 
Germany) were used and detection done with the Super Signal West Pico 
Chemiluminescent Substrate according to the manufacturers protocol (Pierce, 
Socochim, Lausanne, Switzerland) by exposure to an X-ray film. 
4.3.4 Immunocytochemistry 
Cells from monoclonal lines were seeded onto 4-well Lab-Tek chamber slides (Nalge 
Nunc, Milian, Geneva, Switzerland) and induced with DOX (0.5 to 1 µg/mL in the 
culture medium) for 24 h for expression of ABC transporters and eGFP. As control, 
non-induced cells were used.  
ABCB1-flag was analysed for plasma membrane localisation with monoclonal mouse 
anti ABCB1 antibody MRK 16 (Alexis Biochemicals, Lausen, Switzerland; dilution: 
1:1000) directed against an extracellular epitope. Incubation with primary antibody 
was done in cell culture medium at 37°C for 1 h before fixation of the cells with 4% 
paraformaldehyde (PFA) in phosphate buffer (pH 7.4) for 10 min at room temperature 
(RT). Cy3 coupled goat anti-mouse secondary antibody (Jackson ImmunoResearch, 
Suffolk, UK; dilution: 1:500 in 5% w/v milk in PBS, 1 h, RT) was used for 
immunofluorescence detection.  
ABCC1-flag membrane localisation was analysed by labeling ABCC1 after methanol 
fixation (30 s, -20°C) with monoclonal rat anti-ABCC1 antibody (Research Diagnostics 
Inc, Concord MA, USA. ; dilution: 1:100 in 5% w/v milk in PBS, 1 h, RT) recognizing 
an intracellular epitope, and co-labeling of the zona occludens protein ZO-1 with 
rabbit anti-ZO-1 (Zymed Laboratories, San Francisco CA, USA; dilution: 1:1000 in 5% 
w/v milk in PBS, 1 h, RT). For immunofluorescent detection Cy3-coupled goat anti-rat 
and Cy5-coupled goat anti-rabbit antibodies (Jackson ImmunoResearch, 1:500 in 5% 
w/v milk in PBS, 1 h, RT) were used.  
Immunofluorescence was visualised by confocal laser scanning microscopy (Zeiss, 
LSM-510 Meta Jena, Germany) using a 100 x objective (numerical aperture 1.4) and 
sequential acquisition of separate channels. The pinhole was set to 1.0 Airy unit for 
each channel, and stacks of confocal sections (512 x 512) spaced by 0.3-0.5 μm were 
acquired at a magnification of 60-150 nm/pixel using the full dynamic range of the 
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photomultiplier. For display, images were processed with the image analysis software 
Imaris (Bitplane, Zurich, Switzerland). Images from both channels were overlaid 
(maximal intensity projection, “section” view) and background was subtracted when 
necessary.   
4.3.5 Drug transport experiments 
50000 (for MDCK-ABCB1 line) or 80000 (for MDCK-ABCC1 line) cells from an 
overnight culture of the respective clonal line were seeded on “Transwell” permeable 
supports (0.4 μm pore sise, polyester membrane, 6.5 mm diameter inserts in 24 well 
plate; Costar, Corning, New York, USA) and allowed to grow in culture medium for 3 
days. Two days after seeding, 24 h prior to the transport assay, they were induced by 
addition of DOX (1 μg/mL for ABCB1 line and 0.5 μg/mL for ABCC1 line) to the 
medium if required. Transepithelial electrical resistance (TEER) was measured in 
Hanks Balanced Salt Solution (HBSS +Ca +Mg) (Gibco, Invitrogen) with an electrical 
volt-ohm meter (EVOM, World Precision Instruments (WPI), Berlin, Germany) and a 
corresponding Endohm-6 tissue resistance measurement chamber (WPI). Only 
“Transwells” with tightly grown cells that had a TEER ≥ 330 Ω*cm2 were included in 
the analysis. When establishing the method, TEER was also measured after transport 
assay. Later on, TEER measurements at the end of the experiment were omitted to 
avoid loss of accuracy in amount of drugs found inside the cells. According to the 
polarisation of MDCK cells, the inside of a “Transwell” insert was defined as apical 
compartment (a) and the volume of the well below the insert was defined as 
basolateral compartment (bl) (Figure 4.1 C). The MDCK cell monolayer comprised the 
third, (intra-)cellular compartment (cells). On the third day after seeding the cells, 
drug transport experiments were performed. They were repeated at least 3 times 
with different culture batches in triplicate each. Substances (see Table 4-1) were 
added to the HBSS either into the apical (200 µL) (apical to basolateral transport (a 
Æ bl)) or the basolateral compartment (700 µL) (basolateral to apical transport (bl Æ 
a)). For every direction and condition (a Æ bl; bl Æ a; 4°C; 37°C), the “Transwells” 
were incubated for either 1 or 2 hours (Data for 2 h time-points not shown). Drug 
transport experiments were done in the presence of inhibitors (see Table 4-1) added 
to the apical and basolateral compartment to block endogenous ABC-transporters 
potentially expressed by MDCK cells. After the incubation, apical and basolateral 
solutions were collected separately and cells were treated with 200 µL 10 x trypsin 
(Gibco, Invitrogen), scratched from the membranes and 10, 11-
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dihydrocarbamazepine (between 0.05 and 5 ng/mL) (dhCBZ; Sigma-Aldrich) was 
added to each sample as internal standard for mass spectrometry (MS) 
measurements. Samples were stored at -80°C before preparation for MS analysis.  
In case of experiments with or without probenecid treatment the cell line MDCK-
ABCB1 was used only in the non-induced state. The procedure was the same as 
above: 50’000 cells were seeded onto “Transwell” permeable supports and grown for 
3 days. On day 2, the medium was changed but no DOX was added. After measuring 
the TEER, the medium was exchanged with HBSS containing either 0.5 mM 
probenecid (stock: 250 mM in dimethyl sulfoxide (DMSO), Sigma-Aldrich) or vehicle. 
Lamotrigine was added (see Table 4-1) only in the apical or the basolateral 
compartment depending on transport direction. No additional inhibitor was added. 
Incubation for both directions and conditions (with or without probenecid) were done 
at 37 °C and 4 °C for 1 hour. 
 
 
 
Table 4-1: Substances and inhibitors used in transport assays: 
 info concentration used with source 
Vinblastine  ABCB1 
substrate 
2 µM, stock 
(1000x) in water 
MDCK-ABCB1 
MDCK-ABCC1 
vinblastine-sulfate, 
Sigma-Aldrich 
Vincristine ABCC1 
substrate 
2 µM, stock (500x) 
in water 
MDCK-ABCC1 vincristine-sulfate, 
Sigma-Aldrich 
Carbamazepine 
(CBZ) 
AED 40 μM, stock 
(1000x) in 100 % 
ethanol 
MDCK-ABCB1 
MDCK-ABCC1 
Sigma-Aldrich 
Lamotrigine  AED 40 µM, stock 
(1000x) in 100 % 
ethanol 
MDCK-ABCB1 
MDCK-ABCC1 
material transfer 
agreement, Desitin 
Pharma GmbH, 
Liestal, Switzerland 
MK571 ABCC 
inhibitor 
50 μM, stock 
(100x) in water 
MDCK-ABCB1 Merck, Darmstadt, 
Germany 
Tariquidar ABCB 
inhibitor 
0.2 μM, stock 
(100x) in 50 % 
acetonitrile 
MDCK-ABCC1 tariquidar-mesilate; 
kind gift of Dr. D. 
Hermann, USZ, 
Zurich, Switzerland 
Probenecid organic 
anion 
transporter 
inhibitor 
0.5 mM, stock 
(500x) in DMSO 
MDCK-ABCB1 
MDCK-ABCC1 
Sigma-Aldrich  
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4.3.6 Sample preparation/extraction for MS 
Cell-fractions were sonicated for 10 s prior to extraction. For CBZ and lamotrigine, the 
compounds (drugs and internal standard) were extracted using 1 volume of ethyl 
acetate (Chromasol V, Sigma-Aldrich) by vigorous vortexing for 30 s. The phases 
were separated by centrifugation at 6000 rpm for 6 min. The upper organic phase 
was dried at 65°C and samples were reconstituted in 50% acetonitrile (Chromasol V, 
Sigma-Aldrich) containing 0.1% formic acid (Sigma-Aldrich) and filtered (Cronus 
regenerated cellulose membrane filters, diameter 4 mm, pore size 0.45 μm, 
Infochroma AG, Zug, Switzerland) prior to LC-MS/MS analysis. 
For the more hydrophilic vinblastine and vincristine, no organic extraction could be 
carried out. Instead, samples were directly supplemented with 1 volume of 
acetonitrile and 0.1% formic acid and filtered prior to MS analysis. 
4.3.7 LC - MS/MS analysis 
The separation of vinblastine and the internal standard dhCBZ was performed on an 
Agilent 1100 liquid chromatography system using an eclipse XDB-C18 reverse phase 
column (Agilent, 4.6 x 150 mm, 5 μm pore size) with a corresponding opti-guard pre-
column. The mobile phase consisted of (A) 0.1% aqueous formic acid (Sigma-Aldrich) 
and (B) acetonitrile containing 0.1% formic acid at a flow rate of 500 μL/min using an 
injection volume of 20 μL. Starting conditions of 50% buffer B were maintained for 2 
min, followed by a linear gradient from 50 to 90% B within 6 min. An isocratic flow of 
90% B was held for 1 min and finally the column was re-equilibrated for 1.5 min with 
50% B. The HPLC system was coupled to a 4000 QTRAP hybrid quadrupole linear ion 
trap mass spectrometer (Applied Biosystems, Carlsbad CA, USA) equipped with a 
TurboV source and electrospray (ESI) interface. Analytes were recorded using 
multiple reaction monitoring (MRM) in positive mode (+MRM) using the following 
source specific parameters: IS 5’500 V, TEM 400°C, curtain gas (CUR = 10), nebuliser 
gas (GS1 = 40), heater gas (GS2 = 50) and collision gas (CAD = 5). The compound 
specific parameters (listed in Table 4-2) for the different substrates were determined 
by direct infusion of standard solutions (100-300 nmol/mL) in acetonitrile at a flow 
rate of 10 µL/min using the quantitative optimisation function of the Analyst software 
1.4.2 (Applied Biosystems). 
 
 
 
 50 
Results: in vitro study Material and Methods 
Table 4-2: Parameters used for MS analysis and quantification of substances: 
Compound  Transition DP  CE CXP EP LOD 
(ng/mL) 
LOQ 
(ng/mL)
Vinblastine 811.5 → 224.2 91 59 18 10 0.7  2.4 
Vincristine 413.3  → 362.1 71 27 10 10 0.03 0.1 
dhCBZ 239.0 → 194.2 26 31 14 10 0.0003 0.001 
CBZ 237.0 → 194.1 26 27 14 10 0.06 0.18 
Lamotrigine 256.04 → 211.0 31 56 14 10 5.2 17.4 
DP (declustering potential), CE (collision energy), CXP (collision cell exit potential), EP 
(entrance potential), LOD (limit of detection), LOQ (limit of quantification) 
 
Vincristine recording was also done in +MRM mode with the following source specific 
parameters: IS 5’500 V, TEM 450 °C, curtain gas (CUR = 10), nebuliser gas (GS1 = 
40), heater gas (GS2 = 50) and collision gas (CAD = 5). Starting conditions of 50 % 
buffer B at a flow rate of 500 μL/min were maintained for 2 min, followed by a linear 
gradient from 50 to 90 % B within 6 min. An isocratic flow of 100 % B was held for 1 
min and finally the column was re-equilibrated for 1.5 min with 50 % B. The injection 
volume was 20 μL. 
CBZ and lamotrigine were also recorded using +MRM with the following source 
specific parameters, listed in the order CBZ- before lamotrigine-settings, if differing: 
IS 5’500 V, TEM 450 °C respectively 400 °C, curtain gas (CUR = 10), nebuliser gas 
(GS1 = 15 or 40 respectively), heater gas (GS2 = 40) and collision gas (CAD = 5). 
Starting conditions of 20 % or 50 % buffer B, respectively, at a flow rate of 400 
μL/min or 500 μL/min were maintained for 2 min, followed by a linear gradient from 
20 to 100 % B, respectively 50 to 90 % B within 3 min. An isocratic flow of 100 % B, 
respectively 90 % B was held for 3 min and finally the column was re-equilibrated for 
3 min with 20 % B or 50 % B respectively. The injection volume was 10 μL for CBZ 
and 20 μL for lamotrigine. 
4.3.8 Assay validation example 
Samples were quantified by determining the area under the curve (AUC) with the 
quantification function of the Analyst® software 1.4.2 (Applied Biosystems), using the 
transitions listed in Table 4-2 for each substrate. The background noise was assessed 
by analyzing a blank area of the chromatogram obtained with the standard curve 
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which was generated using blank samples spiked with a series of concentrations 
ranging from 0.01-10’000 ng/mL depending on the substance. Hence, correlation 
coefficients as well as the limit of detection (LOD) and the limit of quantification 
(LOQ) could be obtained. The LOD was corresponding to a signal-to-noise ratio of 3 
and the LOQ to a signal to noise ratio of 10, respectively.  
4.3.9 Data analysis 
The integrals of the transported substance were compared to the corresponding 
standard curve (ranging from 0.01 to 10’000 ng/mL depending on the substance). 
Best fit was obtained by using a double logarithmic scale with concentrations on the x 
and counts of the AUC on the y axis. The concentrations were calculated using the 
regression curves of the standard curves (x = (y/a)(1/b), where y = ∫AUC, a it the axis 
intercept of the slope at 1 ng/mL, b is the slope) and then multiplied with the dilution 
factor (D) which resulted from the preparation. The concentration of dhCBZ, the 
internal standard (IS), was used to normalise the measurement and exclude 
preparation and pipetting errors. As the absolute values varied between experiments 
the calculated yield of IS (YIS) and the concentrations of the substances were in 
percentages (Ceff = (x * D)/YIS) * 100). These were compared between the three 
compartments to calculate the percentage of total recovered substance for each 
compartment as part of 100 %.   
Each transport experiment was performed in triplicate. These were compared and 
outliers determined using Grubbs outlier test for 3 samples (rm (95%, 3) = 1.153). 
The resulting mean was considered as one experiment. For each condition, at least 
three experiments were performed. 
Statistical analyses to compare means across conditions were done using one-tailed 
Mann-Whitney test (Graph Pad, Prism 4). A P value ≤ 0.05 was considered as 
statistically significant. 
Transport ratios (TRs) for ABCB1, an exporter located on the apical side of cells, were 
calculated as follows: TR = (% substance apicalblÆa)/(% substance basolateral aÆbl). 
TRs for ABCC1, an exporter located on the basolateral side of cells, were calculated as 
follows: TR = (% substance basolateral aÆbl)/(% substance apicalblÆa). The corrected 
TR (cTR) was calculated by dividing the TR obtained from induced cells by the TR 
obtained from non-induced cells. A substance was considered to be a substrate of the 
corresponding transporter, if cTR ≥ 1.5.  
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4.4 Results 
4.4.1 Immunochemical detection of induced 
transporters 
Cell extracts were prepared from induced and non-induced MDCK cells after 24 h 
exposure to DOX or vehicle, respectively. Western blotting using anti-flag antibodies 
revealed strong expression of ABCB1-flag in the MDCK-ABCB1 cell line and ABCC1-flag 
in the MDCK-ABCC1 cell line. No signal was detected in non-induced (vehicle-treated) 
MDCK-ABCB1 or MDCK-ABCC1 cells or in non-transfected cells, indicating absence of 
transcriptional activation in the absence of DOX, as well as specificity of antibodies 
(Figure 4.2 A).  
In preliminary experiments, DOX concentrations were titrated to achieve maximal 
surface expression of the respective ABC transporter in each cell line as assessed by 
ICC. A concentration of 1 μg/mL cell culture medium was found optimal for ABCB1- 
and 0.5 μg/mL for ABCC1 induction (data not shown). Higher DOX concentrations 
resulted in decreased cell surface expression and increased intracellular accumulation, 
possibly due to overload of the protein sorting machinery. Immunofluorescence with 
an antibody targeted to an extracellular epitope of ABCB1 was used to assess its 
distribution in induced cells. The expected polarised localisation of ABCB1 in the apical 
membrane compared to cytoplasmic GFP was evident when examining stacks of 
confocal images along the z-axis (Figure 4.2 B). In case of MDCK-ABCC1 cells, the 
basolateral localisation of ABCC1 immunofluorescence (using an antibody against an 
intracellular epitope) was verified by comparing its localisation to that of the tight-
junction marker ZO-1 (Figure 4.2  C). The specificity of immunofluorescence staining 
was verified in non-induced cells, in which only background staining was observed. 
Examination of both monoclonal cell lines in the microscope revealed, unexpectedly, a 
mosaic-like expression pattern of the recombinant proteins. Therefore, despite 
transcription being driven from a single promoter and the cells being of monoclonal 
origin, it was not possible to achieve a homogeneous expression or to use eGFP 
fluorescence as an index of recombinant transporter expression on a single-cell basis. 
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Figure 4.2: Verification of 
induced expression and 
correct subcellular 
localisation of ABC 
transporters.  
A: Immunoblot analysis of 
cell extracts with anti-flag 
antibodies showing two 
prominent bands around 200 
kDa in induced MDCK-ABCB1 
and MDCK-ABCC1 cells. No 
flag-immunopositiv band 
was found in the non-
transfected MDCK cells 
(middle lanes). The bands at 
42 kDa represent β-actin as 
loading control. B and C: 
Images from confocal laser 
scanning microscopy in top 
and side views (z-stacks) 
showing the expression and 
membrane localisation of 
transporters in transfected 
MDCK cells upon induction of 
gene expression. No signal is 
evident in and non-induced 
cells (low left hand corner). B: ABCB1 (red) localises apically above the cytoplasmic eGFP 
(green) expressed in a co-inducible manner. Scale bars: 30 μm C: ABCC1 localises on the 
basolateral side of cells below the tight junction marked by the protein ZO-1 (blue). Scale 
bars: 20 μm 
 
4.4.2 Design of drug transport experiments 
For transport experiments with ABCB1 and ABCC1, one monoclonal cell line was 
selected for each of them, based on optimal expression levels and subcellular 
targeting, as shown above.  Cells were grown on a filter insert in 24-well plates to 
form a monolayer dividing the well into two compartments: apical (a) and basolateral 
(bl) in addition to the intracellular compartment (Figure 4.1 C). The basolateral part of 
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the cells was in contact with the filter. Each experiment was done in triplicate and in 
parallel at 37º and at 4ºC with cells pre-exposed to DOX (induced) or to vehicle (non-
induced), yielding 12 samples per assay. All drugs were assayed in both directions (a 
Æ bl and bl Æ a) for 1 h and 2 h. Qualitatively similar results were obtained with both 
incubation times, but the variability between experiments was larger after 2 h (data 
not shown). The TEER was stable over 1 h but tended to decrease after 2 h.  All 
results presented here are derived from the 1 h incubation time. 
 
 
Figure 4.3: Verification of 
functionality of MDCK-
ABCB1 cells with 
vinblastine (VB) as 
transport substrate. Data 
represent means of 
percentages of total 
recovered vinblastine from 
the apical, cellular and 
basolateral compartment of 
the ”Transwell”. Error bars 
represent the standard 
deviation (SD) obtained from 
at least 3 experiments, each 
in triplicate. For clarity only 
the percentages of drug 
recovered from the 
compartments where it was 
not added are displayed. Histograms show fractions from apical compartment (dark grey), 
cells (white) and basolateral compartment (light grey) from left to right. Representations of 
fractions from induced conditions are striped, non-induced ones are plain. A: Transport from 
bl Æ a for 1h at 37°C. There is a significant difference between the fractions recovered from 
apical compartments of induced compared to non-induced cells (*P ≤ 0.05, Mann-Whitney). 
B: Transport from bl Æ a for 1h at 4°C. C and D: Transport from a Æ bl at 37°C and 4°C, 
respectively. There are significant differences for all compartments between the transport at 
37°C and at 4°C (*P ≤ 0.05, Mann-Whitney). (*P ≤ 0.05, Mann-Whitney). 
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At the end of each experiment, the samples from the three compartments (apical, 
basolateral, and intracellular) were collected and their drug content analysed by LC-
MS/MS. The concentration of dhCBZ added as internal standard to determine the LOD 
and LOQ was adjusted for each compound separately as their detection sensitivities 
were different (Table 4-2). 
4.4.3 Vinblastine transport in ABCB1-MDCK cells 
To test the functionality of induced ABCB1 expression, we measured transport of 
vinblastine, a known substrate for ABCB1 (Shalinsky et al., 1993), using 0.05 ng/mL 
dhCBZ as internal standard and MK571 as ABCC inhibitor (Table 4-1). To rule out any 
bias by endogenous expression of ABCC proteins, MK571 was added in all 
experiments to both sides of the system. As expected from the apical location of 
ABCB1, vinblastine was transported more efficiently in the bl Æ a direction by cells 
overexpressing ABCB1 (induced) than by control cells (non-induced). The percentage 
of total vinblastine recovered from the apical compartment after 1 h incubation was 
three times higher than that obtained from non-induced cells (4.4% versus 1.4%, P ≤ 
0.05, n = 6, Mann-Whitney, one-tailed) (Figure 4.3 A), representing a cTR of 4.73 at 
37°C (Table 4-3). Strikingly, the intracellular fraction of vinblastine was larger than 
the apical fraction in bl Æ a directed transport, indicating good penetration of the 
drug across the basolateral membrane and intracellular accumulation. However, 
functionality of ABCB1 was also supported by the observation that vinblastine added 
to the apical compartment tended not to enter cells as efficiently in induced cells 
compared to non-induced cells (Figure 4.3 C, P = 0.1). Furthermore, little vinblastine 
reached the basolateral compartment (~ 0.2%) when added to the apical side, 
independently of induction of ABCB1 expression and efficient substrate uptake (4 – 
5% intracellular fraction). This result indicates that only negligible, if any diffusion of 
vinblastine occurred between the monolayer formed by MDCK cells. 
When assayed at 4°C, vinblastine transport was significantly reduced compared to 
physiological temperature for both induced and non-induced cells (Figure 4.3). A 
minute fraction of substrate was transported under these conditions (0.07 – 0.15% in 
bl Æ a direction) but the contribution of ABCB1-overexpression cells was still evident 
(cTR = 2.49). Additionally, compared to 37°C, we found a significantly reduced 
intracellular fraction of vinblastine, suggesting energy-dependent intracellular 
accumulation. Altogether, these findings demonstrate specific, directional, and active 
transport of vinblastine in induced ABCB1-MDCK cells.  
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Figure 4.4: Analysis of 
functionality of transport 
by MDCK-ABCC1 cells. 
Means of fractions of total 
recovered drug (± SD) for 
each compartment are 
displayed. A and B: Transport 
of vincristine (VC) from bl Æ 
a  at 37°C and 4°C, 
respectively. The fraction of 
transported drug is very small 
compared to Figure 4.3. No 
significant differences were 
found between the induced 
and non-induced cells (P = 
0.1, Mann-Whitney). 
Significantly less vincristine is 
transported at 4°C compared 
to 37°C (*P = 0.05, Mann-
Whitney). C and D: Transport 
of vincristine (VC) from a Æ 
bl at 37°C and 4°C 
respectively. Almost nothing 
penetrates the cells. No 
significant differences were 
detected. E and F: Transport 
of vinblastine (VB) from bl Æ 
a at 37°C and 4°C, 
respectively. The only 
significant difference was 
detected between the cellular 
fractions at 37°C and 4°C (*P 
= 0.05, Mann-Whitney). G 
and H: Transport of
vinblastine (VB) from a Æ bl 
at 37°C and 4°C, respectively. No significant differences were detected except between the 
cellular fractions at 37°C and 4°C (*P = 0.05, Mann-Whitney). 
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4.4.4 Vincristine transport in ABCC1-MDCK cells  
The functionality of MDCK-ABCC1 cells was assessed with its substrate vincristine 
(Mao et al., 2000) and with vinblastine (Figure 4.4), using 0.05 ng/mL dhCBZ as 
internal standard for both compounds. Addition of tariquidar in all experiments 
ensured to rule out potential transport by endogenous ABCB1. Unexpectedly, the 
monoclonal cell line selected was found to be highly impermeable for these two 
compounds. Only a minute fraction of vincristine penetrated the cells, in particular 
from the apical side (<1%). Hence, we could not detect significant differences in a Æ 
bl directed transport between the various conditions tested (Figure 4.4 C, D). 
However, in the bl Æ a direction, we detected slightly less transport in the presence 
of ABCC1 and obtained a cTR of 1.92 for vincristine at 37°C (Table 4-4), arguing for 
ABCC1-mediated extrusion. However, due to the small amount of drug transported, 
the differences between induced and non-induced cells were not significant (2.5% 
and 1.5%, respectively, P = 0.1, one-tailed Mann-Whitney; Figure 4.4 A). At 4°C, the 
fraction of drug transported was even smaller than at 37°C (Figure 4.4 B, D). 
The low permeability of this monoclonal cell line was confirmed with vinblastine 
transport assays, especially in the a Æ bl direction (Figure 4.4 G, H) compared to 
ABCB1-MDCK cells. Similar to vincristine, the cTR at 37°C (cTR = 1.69) was 
suggestive of ABCC1-mediated transport, although the differences in drug amounts 
recovered in the three compartments were statistically non-significant when 
compared to non-induced cells (Figure 4.4 E-H). 
4.4.5 Analysis of carbamazepine and lamotrigine as 
substrates for ABCB1 
The results so far indicate that inducible expression of ABCB1 allows measuring 
directional drug transport across a monolayer of MDCK cells. Therefore, we tested 
whether the two AEDs CBZ and lamotrigine are potential substrates of ABCB1 in this 
system. Both drugs were assayed at a concentration comparable to plasma-levels in 
longitudinally treated patients. Thus, they were 20 times more concentrated than 
vincristine or vinblastine. Transport assays were performed with MK571, an inhibitor 
of ABC-transporters of the ABCC subfamily (Table 4-1). The internal standard dhCBZ 
was used in a concentration of 5 ng/mL with the CBZ samples and 1 ng/mL with the 
lamotrigine samples. 
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Figure 4.5: Analysis of CBZ 
(A to D) and lamotrigine 
(Lam) (E to H) transport 
by MDCK-ABCB1 cells. 
Data represent means (± SD) 
of percentages of total 
recovered drug as described 
for Figure 4.3 A and B: 
Transport of CBZ from bl Æ a 
at 37°C and 4°C, respectively. 
C and D: Transport of CBZ 
from a Æ bl at 37°C and 4°C, 
respectively. No significant 
differences were detected 
except between 37°C and 4°C 
for the apical and basolateral 
compartments (*P ≤ 0.05, 
Mann-Whitney). E and F: 
Transport of lamotrigine from 
bl Æ a at 37°C and 4°C, 
respectively. G and H: 
Transport of lamotrigine from 
a Æ bl at 37°C and 4°C, 
respectively. No significant 
differences were detected 
except between 37°C and 4°C 
for the apical and basolateral 
compartments (*P ≤ 0.05, 
Mann-Whitney). 
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CBZ: No selective CBZ transport by ABCB1 could be detected as CBZ accumulation in 
apical, cellular and basolateral compartments did not differ significantly between 
ABCB1-expressing (induced) and control (non-induced) cells as shown in Figure 4.5 A-
D. 
Accordingly, the cTR calculated for CBZ was around 1 (Table 4-3). However, a large 
fraction of CBZ was transported across the cells, independently of ABCB1 induction. 
CBZ transport was temperature-sensitive, evident by roughly 2.5  – 3 fold reduction of 
bl Æ a and a Æ bl transport at 4°C compared to 37°C (P ≤ 0.05, one-tailed Mann 
Whitney) (Figure 4.5 B, D). Transport was directional, with about twice as much CBZ 
being transported from bl Æ a (~ 15% of total recovered CBZ in the apical 
compartment) than in the a Æ bl direction (~ 7% recovered in the basolateral 
compartment) (Figure 4.5 A, C). This difference also holds true at 4°C (~ 6% found 
apicallyblÆa; ~ 2 - 3% found basolaterallyaÆbl; Figure 4.5 B, D). A substantial passive 
transport of CBZ remained evident at 4°C, as expected for a lipophilic drug. 
Additionally, it is noticeable that the intracellular fraction of CBZ (~ 1 – 2% of total 
CBZ independently of transport direction and temperature), represents a high 
concentration, which would be available for transport by ABCB1. Altogether, these 
results suggest that endogenous transporters contribute to bidirectional CBZ 
translocation across MDCK cell monolayers, whereas overexpression of ABCB1 could 
not be shown to influence it. 
Lamotrigine: ABCB1 likewise could not be shown to influence lamotrigine transport. 
As shown in Figure 4.5 E-H, there was no significant difference between induced and 
non-induced cells and the cTR was close to 1 (Table 4-3). Similar to CBZ, lamotrigine 
transport was found to be strongest in the bl Æ a direction. About 20% of total 
lamotrigine was recovered in the apical compartment after bl Æ a directed transport, 
compared to about 5% in the opposite direction (Figure 4.5 E, G). Moreover, the cells 
were even more permeable to lamotrigine than to CBZ when assayed at 37°C. 
Lamotrigine transport was also temperature-sensitive independently of induction of 
ABCB1 expression. The transport rate was reduced between 5 fold (bl Æ a) and 10 
fold (a Æ bl) (P ≤ 0.05, one-tailed Mann-Whitney) at 4°C compared to 37°C. The 
fraction of lamotrigine transported at 4°C in the bl Æ a direction (~ 4%) and in the a 
Æ bl direction (~ 0.5%) (Figure 4.5 F, H) was smaller than that measured for CBZ 
(Figure 4.5 G and H), indicating that lamotrigine does not readily cross the cells by 
passive diffusion, despite its limited solubility in water.  
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Table 4-3: Transport ratios and corrected transport ratio for transport in ABCB1-
MDCK cells (in bl Æ a direction for an apically expressed exporter). 
(TR = apicalblÆa / basolateralaÆbl; cTR = TRind / TRnon-ind) 
 Vinblastine  Carbamazepine  Lamotrigine  
 37°C 4°C 37°C 4°C 37°C 4°C 
TR 
induced 
30.88 6.55 1.81 1.94 3.68 7.75 
TR non- 
induced 
6.52 2.63 2.57 3.04 4.71 6.95 
cTR 4.73 2.49 0.71 0.64 0.78 1.12 
 
4.4.6 Analysis of carbamazepine and lamotrigine as 
substrates for ABCC1 
Despite the very low permeability of the ABCC1-MDCK cell clone used for vincristine 
and vinblastine, transport of CBZ and lamotrigine, which are less hydrophilic, was 
assessed in these cells as well. Tariquidar was added during the transport as ABCB 
inhibitor and the concentrations of dhCBZ as internal standard were again 5 ng/mL 
for CBZ and 1 ng/mL for lamotrigine measurements. The amounts of AED were 
adjusted to plasma levels from patients and were 20 x higher than concentrations of 
vinblastine or vincristine. 
CBZ: The fraction of CBZ actively transported at 37°C in either direction (Figure 4.6 A 
and C) across the MDCK-ABCC1 cell monolayer was much larger than that of 
vincristine and vinblastine. ABCC1-MDCK cells even transported more CBZ than 
MDCK-ABCB1 cells, independently of induction. These differences indicate that CBZ 
readily penetrates into MDCK cells and that endogenous transport mechanisms can 
vary among clonal cell lines, underscoring the importance of using an inducible 
system to assess drug transport with an appropriate control. Additionally, we again 
observed that MDCK cells are generally more permeable for CBZ in bl Æ a direction 
than in a Æ bl. This difference was also seen at 4°C. 
As for ABCB1, CBZ could not be demonstrated to be transported by ABCC1 in induced 
cells (Figure 4.6 A-D). The cTR was around 1 (Table 4-4). Failure to detect ABCC1-
mediated transport occurred despite the substantial amount of CBZ accumulated 
intracellularly  (1%).  Again, a pronounced difference between CBZ  transport at 37°C  
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Figure 4.6: Analysis of CBZ 
(A-D) and lamotrigine (Lam) 
(E-H) transport by MDCK-
ABCC1 cells. Representations of 
means (± SD) of fractions of 
recovered drug as described for 
Figure 4.3. A and B: Transport 
of CBZ from a Æ bl at 37°C and 
4°C, respectively. C and D: 
Transport of CBZ from bl Æ a at 
37°C and 4°C, respectively. No 
significant differences were 
detected except between 37°C 
and 4°C for the apical and 
basolateral compartments (*P ≤ 
0.05, Mann-Whitney). E and F: 
Transport of lamotrigine from a 
Æ bl compartment at 37°C and 
4°C, respectively. G and H: 
Transport of lamotrigine from bl 
Æ a at 37°C and 4°C, 
respectively. No significant 
differences were detected except 
between 37°C and 4°C for the 
basolateral and apical 
compartments in the induced 
case of apical to basolateral 
directed transport and for apical 
and basolateral compartments in 
both cases, in the basolateral to 
apical direction (*P ≤ 0.05, 
Mann-Whitney). 
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Table 4-4: Transport ratios and corrected transport ratio for transport in MDCK- 
 ABCC1 cells (in a Æ bl direction for a basolaterally expressed exporter). Values 
below 1 indicate transport in the opposite direction, here in bl Æ a. 
 (TR = basolateralaÆbl / apicalblÆa; cTR = TRind / TRnon-ind) 
 Vincristine Vinblastine Carbamazepine Lamotrigine 
 37°C 4°C 37°C 4°C 37°C 4°C 37°C 4°C 
TR 
induced 
0.17 0.31 0.50 0.34 0.38 0.36 0.01 0.08 
TR non- 
induced 
0.09 0.20 0.29 0.76 0.39 0.25 0.01 0.28 
cTR 1.92 0.67 1.69 0.45 0.98 1.47 0.92 0.27 
 
and at 4°C was observed independent of induction of ABCC1-expression, pointing to 
endogenous active transport mechanisms in the MDCK-ABCC1 cell line. The residual 
transport at 4°C (~ 15% total recovered CBZ apicallyblÆa; ~ 4% basolaterallyaÆbl; 
Figure 4.6 B and D) was reduced 2.3-fold for a Æ bl and 1.5-fold for bl Æ a as 
compared to 37°C. 
Lamotrigine: The fraction of lamotrigine recovered apically (~25%) following bl Æ a 
directed transport was very high, whereas only minute amounts of lamotrigine 
reached the basolateral side (~ 0.3%) when added to the apical compartment (Figure 
4.6 E and G). These results show that the MDCK-ABCC1 cell line formed a tight 
barrier and had a strong directional preference for lamotrigine transport. The 12-fold 
reduction in bl Æ a transport at 4°C (~ 2% lamotrigine found apicallyblÆa; ~ 0.1 – 
0.6% found basolaterallyaÆbl) (Figure 4.6 F and H) revealed that lamotrigine was 
mainly transported in an energy-dependent manner. The small fractions found inside 
the cells (~ 1.5% for bl Æ a; ~ 0.2% for a Æ bl) compared to what was found on the 
receiving side also hint to powerful active extrusion mechanisms. 
Despite considerable intracellular accumulation of lamotrigine, comparison of induced 
and non-induced cells yielded a cTR around 1 (Table 4-4) and no significant 
differences between total recovered drug in the induced and the non-induced state 
were detected (Figure 4.6).  
4.4.7 Analysis of endogenous transport mechanisms 
As we observed that CBZ and even more so lamotrigine are efficiently transported 
across MDCK cells at 37°C independently of ABCB1 and ABCC1 by energy-dependent 
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mechanisms, we attempted to block this endogenous transport with probenecid, a 
broad-band inhibitor of organic anion transporters.  
These experiments were conducted for lamotrigine using non-induced cells derived 
from the ABCB1 monoclonal line. In this assay no additional inhibitors were used. In 
the absence of probenecid, we observed bi-directional transport of lamotrigine at 
37°C, which was largely abolished in experiments performed at 4°C and was stronger 
in the bl Æ a direction, as observed in control cells (see Figure 4.5). Addition of 
probenecid (0.5 mM) to both compartments during lamotrigine transport had no 
statistically significant effect on the relative lamotrigine concentration recovered in the 
various compartments, although the variability between experiments was rather high 
for no discernable technical reason (Figure 4.7). 
 
 
 
Figure 4.7: Analysis of 
endogenous lamotrigine 
(Lam) transport. To 
inhibit endogenously 
expressed organic anion 
transporters, probenecid 
was added during the 
transport experiments (+ 
probenecid) and compared 
to vehicle treated controls (- 
probenecid). For each case 
4 trials were performed on 
different days, each in 
triplicate. Data represent 
means (± SD) of 
percentages of total 
recovered drug for each 
compartment (apical, cells, 
basolateral). A and B: Transport of lamotrigine from the bl Æ a at 37°C and 4°C, respectively. 
C and D: Transport of lamotrigine from a Æ bl at 37°C and 4°C respectively. No significant 
differences were detected except between 37°C and 4°C for the apical and basolateral 
compartments (P ≤ 0.05, Mann-Whitney).  
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4.5 Discussion 
We established an in vitro model which is well suited to study transport of drugs by 
either human ABCB1 or ABCC1 through a biological barrier. Upon induction with DOX, 
the multidrug transporters are expressed and trafficked to their appropriate position. 
By testing the ABCB1 transport system with a known substrate, and at 37°C and at 
4°C, we could show that our in vitro BBB model is functional and specific. Induction of 
ABCB1 led to a significant increase in vinblastine extrusion, resulting in a cTR of 4.7. 
Control experiments of vincristine and vinblastine transport by ABCC1-MDCK cells 
were not satisfactory due to insufficient penetration of these drugs unlike that seen in 
ABCB1 cells. We found no evidence for ABCB1- or ABCC1-mediated transport of CBZ 
or lamotrigine, suggesting that these AED may not be substrates of ABCB1 or ABCC1. 
However, we observed in both cell lines a prominent active transport of CBZ and 
lamotrigine independently of ABCB1 or ABCC1 expression, which might have obscured 
a contribution of the induced transporters. Our results confirm previous findings for 
CBZ (Owen et al., 2001; Baltes et al., 2006) but contrast with a recent report of 
lamotrigine transport by ABCB1 (Luna-Tortos et al., 2008). 
4.5.1 Characterisation of basal transport in non-
induced MDCK cells 
A major advantage of an inducible expression system is that the same cell clone used 
to study transport serves as a baseline control for experiments conducted in parallel 
under identical conditions. Importantly, recombinant ABCB1 and ABCC1 were not 
detectable in non-induced cells, confirming that the promoter used here was silent in 
the absence of DOX. Furthermore, the sensitivity of LC-MS/MS provided reliable 
results even for the intracellular compartment or for conditions under which little 
transport occurred, such as 4ºC. A further prerequisite for measuring drug extrusion 
is the presence of a tight barrier preventing passive drug diffusion between cells. 
MDCK cells proved highly suitable for this purpose, since they appeared largely 
impermeable for the four substrates tested, but exhibited distinct, energy-dependent 
bidirectional transport capacity independently of ABCB1 and ABCC1 induction. 
Nevertheless, the control experiments with vincristine in the ABCC1 system revealed 
the limitations of this approach. The MDCK-ABCC1 cell line was found to be virtually 
impermeable for vincristine and vinblastine. This result indicates that these substrates 
did not penetrate intracellularly, and therefore could not be assayed reliably. The 
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reasons why vinblastine was transported into MDCK-ABCB1, but not into MDCK-
ABCC1 cells, is unknown.  However, this finding shows that different clones of MDCK 
cells cannot readily be compared with each other, stressing the need for inducible 
expression to have an adequate control. Despite the limited penetration of vincristine 
into MDCK-ABCC1 cells, the cTR pointed towards active extrusion from induced cells.  
Both cell lines exhibited a clear directional preference for transport of CBZ and 
lamotrigine at physiological temperatures, with more substrate crossing the cells in 
the bl Æ a direction than vice-versa. The large fraction of lamotrigine transported, 
notably by the MDCK-ABCC1 cell line, suggests at first glance that the monolayer 
might not be impermeable. However, only a small fraction (<0.3%) was translocated 
in the opposite direction, ruling out this concern. In the a Æ bl directed transport, the 
fraction of lamotrigine recovered intracellularly (~ 0.2 – 0.3%) was lower than in the 
opposite direction (~ 1 – 1.5%) for both the MDCK-ABCB1 and the MDCK-ABCC1 
lines. From these observations, we conclude that directional transport is ensured by 
endogenous mechanisms facilitating basolateral drug penetration and apical 
extrusion.  
Passive drug diffusion across the monolayer contributes to most drug transport under 
conditions where energy-dependent pumps are inhibited, such as lowering the 
temperature to 4°C. This might also affect membrane permeability by changing its 
physico-chemical properties and lateral mobility of its constituent lipids and proteins, 
thereby contributing to reduced drug transport at 4°C. The high fraction of CBZ 
translocated in these control experiments suggested that CBZ easily crosses lipid 
bilayers, despite being more water-soluble than lamotrigine. Interestingly, we still 
observed a directional transport preference for both drugs at 4°C. This effect likely 
reflects the larger area of the basolateral membrane compared to the apical 
membrane, offering more surface for passive diffusion (von Bonsdorff et al., 1985). 
Another possibility is the different molecular composition of the apical and basolateral 
membranes (Richardson and Simmons, 1979, van Meer and Simons, 1982) which 
might favor passive diffusion through the basolateral membrane.  
The prominent endogenous transport capacity of both cell lines for CBZ and 
lamotrigine prompted us to test whether organic anion transporters, such as OAT1, 
which is highly abundant at the basolateral membrane of kidney tubular cells 
(Burckhardt and Burckhardt, 2003) mediate this effect. Addition of probenecid, a 
broad-band inhibitor of OATs, to the lamotrigine transport assays resulted in variable 
effects, with a blockade of basolateral to apical transport being evident in 2/4 tests. 
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The reasons for this variability could not be determined. It should be noted, however, 
that probenecid has been reported to enhance ABCC2 activity (Huisman et al., 2002, 
Zimmermann et al., 2008). Considering the fact that MDCK cells display a range of 
endogenous drug carriers including multidrug transporters like ABCC2 (Goh et al., 
2002), it is conceivable that the inhibition of OATs by probenecid might have been 
masked by activation of ABCC2 and possible transport mediated by organic anion 
transporter polypeptides (OATPs) which are, among many other transporters, also 
present in MDCK cells (Ito et al., 2005)  
4.5.2 Transport capacity of induced cells 
Analysis of transporter expression upon DOX induction by Western blotting and 
immunocytochemistry revealed a strong expression and correct subcellular localisation 
of recombinant ABCB1 and ABCC1 (Figure 4.2). When tested with vinblastine, a 
known substrate for ABCB1, the functionality of recombinant ABCB1 could be 
demonstrated. The cTR obtained in this system (4.73 at 37°C) was slightly higher 
than that reported in  previous studies (Baltes et al., 2007, Luna-Tortos et al., 2008). 
It was striking that a large fraction of drug (~ 6 – 8%; bl Æ a) could accumulate 
intracellularly in the presence of ABCB1; this result suggests that the endogenous 
transporter(s) responsible for vinblastine uptake are more efficient than ABCB1-
mediated extrusion. Despite this positive control, overexpression of either ABCB1 or 
ABCC1 had no influence on CBZ or lamotrigine transport, irrespective of the direction, 
duration of the assay, or temperature (Figure 4.5 &Figure 4.6; Table 4-3 &Table 
4-4). These negative results argue against ABCB1- and ABCC1-mediated CBZ and 
lamotrigine transport under the present experimental conditions. However, we cannot 
rule out that the strong endogenous transport present in MDCK cells might mask 
transport by ABCB1 or ABCC1. Especially since a recent study found weak, tariquidar-
sensitive, directional lamotrigine transport by ABCB1 in a concentration equilibrium 
assay after prolonged transport duration (Luna-Tortos et al., 2008). We found 
directional lamotrigine transport as well, but independent of ABCB1 induction. 
In brain, ABCB1 is localised on the apical, luminal side of microvessels. Our findings 
indicate that ABCB1 might not be involved in epilepsy-related pharmacoresistance to 
CBZ or lamotrigine; it cannot be excluded that it may still play a role in 
pharmacoresistance to other AEDs, or that its function in endothelial cells is regulated 
differently than in MDCK cells. In case of ABCC1, its basolateral targeting results in an 
opposite distribution in endothelial cells (brain side) and choroid plexus epithelial cells 
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(blood side). Therefore, ABCC1-mediated drug extrusion might occur at the blood-
cerebrospinal fluid barrier. In line with this possibility, ABCC1 may even play a role in 
delivering drugs to the brain, as shown after ischemia (Kilic et al., 2008). Although 
our results do not demonstrate its participation in CBZ and lamotrigine transport; it 
remains to be analysed whether ABCC1 might play a role in refractoriness to AED 
treatment.  
4.5.3 Conclusions 
To sum up, we have established an inducible in vitro model of the BBB which is 
suitable to study the substrate specificities of recombinant ABC-transporters with high 
sensitivity. With this system we found no evidence that ABCB1 or ABCC1 are involved 
in the transport of CBZ and lamotrigine. We can not exclude that other, so far 
undetermined transporters present at the BBB, might play a central role in drug-
refractory epilepsy. Possible candidates include other multidrug transporters of the 
ABC superfamily, which have been found to play a role in the limited access of the 
drug topotecan to the brain (de Vries et al., 2007). Alternatively, drug extrusion 
mediated by ABCB1 and ABCC1 from endothelial cells might be dependent on 
mechanisms that are absent in MDCK cells. 
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5.1 Abstract 
Purpose: It has been hypothesised that pharmacoresistance to antiepileptic drugs 
(AEDs), which occurs frequently in temporal lobe epilepsy (TLE), underlies insufficient 
bioavailability of the drugs at the epileptic focus. This could be explained by export of 
drugs at blood-brain barrier (BBB) level. In this regard the focus of many studies was 
laid on an involvement of multidrug transporters of the ATP-binding cassette (ABC) 
family which are expressed at the BBB. Understanding a possible interaction of AEDs 
with multidrug exporters is crucial for future development of better treatments. Here, 
we aimed to investigate the role of the ABC transporter Abcb1a on carbamazepine 
(CBZ) resistance in a mouse model of TLE.  
Methods: The effect of CBZ on healthy animals was analysed by studying its 
sedative action. Hence, general activity and locomotion was assessed in wild type 
(WT) and transporter-deficient mice. To study the involvement of Abcb1a in 
pharmacoresistance, WT and abcb1a0/0 mice were rendered epileptic by 
intrahippocampal kainate (KA) injection and the effect of CBZ on seizure frequency 
was analysed. 
Results: Treatment with 5 or 10 mg/kg CBZ produced strong sedation in all 
genotypes. In epileptic mice, effect of CBZ on seizure frequencies varied between 
genotypes, but differences could not clearly be assigned to the lack or presence of 
Abcb1a.  
Discussion: Genotype-specific differences hint to an involvement of Abcb1a in 
resistance to AED. However, this could not be unambiguously demonstrated, pointing 
to an involvement of additional mechanisms. 
Key words: temporal lobe epilepsy, intrahippocampal kainic acid injection, mouse 
model, antiepileptic drug resistance, ABC transporter 
 
 
 71
Results: in vivo study Introduction 
 
5.2 Introduction 
Temporal lobe epilepsy (TLE) with hippocampal sclerosis (HS) is a common type of 
focal epilepsy and often associated with pharmacoresistance. The mechanisms 
underlying medically intractable seizures are elusive, since patients typically do not 
respond to a broad range of antiepileptic drugs (AEDs) with various modes of action. 
Two major hypotheses have been proposed: i) Changes in drug targets which may be 
pre-existent or derive from neuropathological alterations in the epileptic brain 
(Jandova et al., 2006). ii) Impaired penetration of AEDs into the brain, caused for 
instance by drug-metabolism in the blood-brain barrier (BBB) or by overexpression of 
functional multidrug exporters (Loscher, 2002, Sisodiya et al., 2002). Evidence 
supporting an increased expression of multidrug transporters of the ATP binding 
cassette (ABC) superfamily come from analyses of brain tissue from patients with 
drug-resistant epilepsy (e.g. (Dombrowski et al., 2001, Sisodiya et al., 2002) and 
experimental studies showing seizure-induced expression of specific ABC transporters 
in animal models of TLE (Zhang et al., 1999, Rizzi et al., 2002, Sills et al., 2002, Volk 
et al., 2004). 
Among the best characterised ABC transporters, the multidrug resistance protein 
ABCB1 (MDR1 or P-gp) is highly abundant in blood-tissue barriers such as the BBB 
and in organs with secretory functions where its main physiological role is to extrude 
xenotoxic compounds. Rodents have two isoforms, Abcb1a and Abcb1b, encoded by 
distinct genes, with complementary tissue distribution. Mainly Abcb1a is present at 
the BBB (Schinkel et al., 1994), localised on the luminal (apical) membrane of brain 
microvessel endothelial cells (Soontornmalai et al., 2006, Roberts et al., 2008).  
ABCB1 extrudes a wide range of structurally and functionally diverse compounds and 
can render cancer cells resistant to certain drugs when overexpressed; hence it might 
play a role in resistance to AEDs (Kwan and Brodie, 2005). However, data about 
transport of AEDs is controversial. Carbamazepine (CBZ), a first line AED for the 
treatment of partial complex seizures, was not found to be an ABCB1 substrate using 
several in vitro approaches, or in vivo using healthy abcb1a/1b0/0 mice (Owen et al., 
2001a, Baltes et al., 2006, Luna-Tortos et al., 2008, Rivers et al., 2008) Nevertheless, 
in another study using microdialysis in rat brain, higher levels of CBZ were found if 
Abcb1 was blocked by verapamil infusion (Potschka et al., 2001). Additionally, a study 
conducted in abcb1a0/0 mice reported higher brain/serum concentration ratios for CBZ 
and other AEDs compared to wild type (WT) despite comparable serum levels (Sills et 
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al., 2002). Irrespective of these controversies, other ABC transporters possibly 
involved in AED resistance include ABCC1 (Mrp1) and ABCC2 (Mrp2) (Abcc1 and 
Abcc2 in rodents) of the ABCC subfamily (Loscher and Potschka, 2002), as well as 
breast cancer resistance protein (BCRP or ABCG2) (Aronica et al., 2005, van Vliet et 
al., 2005). 
Here, we aimed to clarify the role of multidrug transporters in CBZ resistance. The 
TLE model based on a unilateral intrahippocampal injection of KA in adult mice has 
the advantage to produce a focal lesion and induce frequent recurrent seizures 
(typically 30 - 100/hour) (Arabadzisz et al., 2005). This model is well suitable to study 
the effect of AEDs on TLE. We have shown previously that CBZ, as well as valproate 
and phenytoin, but not diazepam, failed to suppress recurrent spontaneous seizures 
in this model (Riban et al., 2002, Gouder et al., 2004), providing an excellent 
opportunity to replicate such experiments in mutant mice.  
To evaluate the role of multidrug transporters in restricting brain access of CBZ during 
physiological and pathophysiological conditions, we analysed here the sedative action 
of CBZ in healthy animals and its anti-convulsive action in the intrahippocampal KA 
mouse model of TLE. Analysis of general motor activity and locomotion following 
systemic CBZ administration was taken as surrogate for sedation (Trevor and Way, 
1995). Mutant mice lacking the abcb1 or abcc1 genes generated in the FVB strain 
were compared to WT FBV mice and to C57BL6/J mice. We have shown previously 
that Abcc2, while normally expressed in liver and kidney, is not detectable 
immunohistochemically in the BBB of FVB mice (Soontornmalai et al., 2006), 
suggesting a potential absence of Abcc2 in the BBB. The involvement of Abcb1a in 
resistance to the antiepileptic action of CBZ was analysed in KA-treated mice 
displaying chronic recurrent seizures. Hence, seizure frequency and duration were 
measured by electroencephalographic (EEG) recordings before and after treatment 
with CBZ or vehicle in abcb1a0/0, FVB, and NMRI mice. The latter served as baseline 
for comparison with previous studies (Riban et al., 2002, Gouder et al., 2004), 
whereas FVB mice provided a measure of the potential role of Abcc2 in influencing 
the action of CBZ. 
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5.3 Materials and methods 
5.3.1 Animals 
Adult mice were purchased from commercial suppliers: Swiss NMRI (Harlan, Horst, 
The Netherlands) served as WT control in the TLE model. C57BL/6J (Jackson 
Laboratories, Bar Harbor, USA) were used as WT control in behavioural experiments 
as they are an inbred strain and mice are similar in size to FVB mice (Taconic Farms, 
Lille Skensved, Denmark). FVB is the WT background strain of the transporter-
deficient abcb1a0/0 and abcc10/0 mice (Taconic Farms). Mouse lines were maintained 
at the Institute of Pharmacology and Toxicology, University of Zurich. Mice were 
housed in a 12 h light-dark cycle with free access to food and water. All procedures 
were approved by the local veterinary authorities and were performed in accordance 
with the European Community Council Directive (86/609/EEC). A maximum of 36 
animals per genotype was used for this study. 
5.3.2 Measurement of general motor activity and 
locomotion 
Measurement of motor activity in rodents represents a standard behavioural assay for 
testing the sedative potential of drugs (Trevor and Way, 1995). General motor activity 
(including exploration and grooming) and locomotion were measured in four 
genotypes (n = 16 per genotype, all male), C75BL/6, FVB, abcb1a0/0 and abcc10/0 
mice to assess the sedative action of CBZ. Mice were housed individually in circular 
arenas for 1 week prior to the start of the experiments to habituate and were kept 
there all the time. Activity recordings were taken over three hours in the individual 
automated circular arenas equipped with four equidistant photocells (Imetronic, 
Pessac, France). Locomotion was scored by counting the number of interruptions of 
two consecutive photocells, whereas general motor activity was scored when only one 
photocell was interrupted. CBZ in 2-hydroxypropyl-β-cyclodextrin complex (HBC) 
(RBI, Natick, MA, U.S.A.) was dissolved in distilled water at a final concentration of 
2.5 mg/mL (0.5 mL/kg). Mice received an i.p. injection of either vehicle or CBZ (5 
mg/kg and 10 mg/kg) and were placed back into their individual circular arena. Each 
animal served as its own control by comparing its behaviour following vehicle injection 
to that after either lower dose or higher dose of CBZ with an interval of two days 
between injections. Statistical analysis of paired treated groups was performed using 
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two-way repeated measure analysis of variance (ANOVA) for comparison between the 
four genotypes (GraphPad, Prism 4). Post-hoc comparisons versus control conditions 
(vehicle) were performed using the Bonferroni test (GraphPad, Prism 4, La Jolla, CA, 
USA). Statistical significance was set at P ≤ 0.05. 
5.3.3 Surgery and electrode implantations 
A new group of female mice of the NMRI, FVB and abcb1a0/0 genotypes was used for 
treatment with KA. Mice were anaesthetised with 2.5 – 3% Isofluorane (Baxter, 
Volketswil, Switzerland) and each mouse was stereotactically injected into the right 
dorsal hippocampus (anteroposterior (AP) = −1.8 mm, mediolateral (ML) = −1.6 mm, 
dorsoventral (DV)= −2.0 mm, with bregma as reference) with 140 nL of a 5 mM 
solution of kainic acid (KA) (Tocris, Lucerna Chem AG, Lucerne, Switzerland) in saline 
(0.9% NaCl, i.e., 1 nmol). For EEG recordings, mice were implanted under 
anaesthesia with bipolar electrodes aimed at the right dorsal hippocampus, using the 
same coordinates (AP = −1.8 mm, ML = −1.6 mm, DV = −2.0 mm), either 
immediately after KA injection or two weeks later, as described (Riban et al., 2002). 
Following surgery, the mice were allowed to recover from anaesthesia, injected with 
1mg/kg buprenorphine (Temgesic, Essex Chemicals, Lucerne, Switzerland) and then 
returned to their home cages with daily monitoring of wellbeing.  
5.3.4 Electroencephalographic recordings and drug 
administration 
EEGs were recorded in freely moving KA-treated mice using a digital acquisition 
system (AcqKnowledge MP100, Biopac Systems Inc., Santa Barbara, CA, USA; 
sampling rate, 200 Hz). Recordings were performed following habituation of the mice 
to the test cage, around midday to minimise potential circadian variations. To assess 
the effects of AEDs on the frequency and duration of recurrent seizures 8 - 14 mice 
per genotype were recorded at three weeks post KA treatment. EEG recordings were 
analysed off-line and artefacts due to animal movements were discarded. Paroxysmal 
events were defined as seizures when they lasted more than 10 s and were separated 
from each other by intervals of at least 3 s. For each animal, the average number of 
seizures per minute and seizure duration was calculated. Only those with more than 
six epileptic paroxysmal discharges per hour and appropriate anatomical lesion in the 
hippocampus (n = 8 - 10, per genotype) were included in the study. To assess the 
effect of ABC transporters on drug resistance, pure CBZ (Sigma-Aldrich, Buchs, 
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Switzerland) was dissolved in 60% PEG400 (Sigma-Aldrich) in distilled water at a final 
concentration of 10 mg/mL. This formulation allowed to administer higher doses than 
in previous studies (Riban et al., 2002, Gouder et al., 2004).  A dose of either 20 
mg/kg or 40 mg/kg of CBZ or vehicle only was injected i.p. in randomised order 
during the EEG recording session. Mice were left to recover for at least two days 
between two sessions. Prior to drug treatment, baseline EEG of seizure activity was 
recorded for 180 min, and following drug administration the animals were recorded 
for a further 180 min. Each animal was thus used as its own baseline control. For 
some mice not all drug-concentrations could be tested due to loss of the implanted 
electrodes. A final number of four to seven mice per genotype and condition could be 
evaluated. 
5.3.5 Statistical analysis of drug effects 
The effects of CBZ were assessed by comparing the frequency and duration of 
hippocampal paroxysmal discharges recorded during the first 100 min period post-
drug administration, with seizures recorded prior to drug injection. Counting was 
started 15 min after drug administration to rule out effects due to the stress of 
injection and handling. Due to large inter-individual differences in seizure frequency, 
the baseline was normalised to 100% for quantification. Statistical analysis to identify 
effects of treatment or genotype was done by two-way ANOVA followed by a post-hoc 
Bonferroni test to compare the effect of drug to vehicle (GraphPad, Prism 4). Analysis 
of effect to baseline was done by two-tailed Wilcoxon signed rank test (GraphPad, 
Prism 4). Significance level was set at P ≤ 0.05.  
5.3.6 Histological controls 
After completion of the experiments (4 - 5 weeks after KA injection), mice were 
deeply anaesthetised with pentobarbital (Nembutal, 40 mg/kg i.p.) and killed by 
decapitation. The brains were rapidly excised and frozen with powdered dry ice. 
Parasagittal sections were cut at 14 μm with a cryostat, mounted onto gelatine-
coated slides and dried at room temperature for approximately 12 h. Histological 
analysis was performed after Nissl (cresyl violet) staining to verify the location of the 
bipolar electrode and the morphological alterations caused by KA injection. 
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5.4 Results 
5.4.1 Strain-dependent sedative effects of 
carbamazepine  
Treatment with CBZ can cause adverse side-effect at the therapeutic dose, including 
sedation, ataxia, dizziness, and visual disturbances (Albani et al., 1995).To evaluate 
the potential role of Abcb1, Abcc1 and Abcc2 in limiting the action of CBZ in the brain, 
we measured its sedative effect in C57BL/6J, FVB, abcb1a0/0 and abcc10/0 mice during 
the light-phase using an automated device to track general motor activity and 
locomotion (Figure 5.1). Data analysis was performed in the time-window between 15 
and 45 min after CBZ administration (Figure 5.1 B) to avoid inclusion of the stress-
induced increase in activity caused by the injection (Figure 5.1 A).  
CBZ administration caused a marked decrease in general activity and locomotion 
during the entire 45 min period analysed. Already at a dose of 5 mg/kg of CBZ, two-
way ANOVA revealed a significant genotype effect on general activity (F3,28 = 11.99, P 
< 0.0001; n=8 per genotype) and on locomotion (F3,28 = 4.664, P = 0.0091) as well 
as a significant treatment effect on general activity (F1,28 = 44.67, P < 0.0001) and on 
locomotion (F1,28 = 20.92, P < 0.0001). This was evidenced by reduction of both 
general activity as well as locomotion (Figure 5.1 B) in FVB, abcb1a0/0 and abcc10/0 
mice (post-hoc Bonferroni, P < 0.05), but not in C57BL/6J mice.  
At a dose of 10 mg/kg, CBZ-induced sedation was more pronounced (two-way 
ANOVA, drug effect on general activity: F1,28 = 132.4, P < 0.0001; drug effect on 
locomotion: F1,28 = 67.04, P < 0.0001) and no genotype effect was observed, since all 
four strains were affected to the same extent for the locomotor activity (two-way 
ANOVA, not significant (ns)), whereas slight differences in general activity were seen 
between genotypes (F3,28 = 4.317, P = 0.0127) (Figure 5.1 B).  
These results show that WT and mutant mice derived from the FVB strain are more 
sensitive to moderate concentrations of CBZ than C57BL/6J mice, even though 
activity levels after vehicle treatment were similar across all genotypes. Neither 
Abcb1a nor Abcc1 appear to reduce the sedative action of CBZ in this test, whereas 
the higher sensitivity of FVB mice compared to C57BL6/J mice to a low dose of CBZ 
might be due to the absence of Abcc2 at the BBB. 
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Figure 5.1: Effect 
of CBZ on 
locomotion and 
general motor 
activity in 
C57BL/6J, FVB, 
abcb1a  and 
abcc1  mice.
0/0
0/0  A: 
Locomotion (± 
standard error of 
the mean (SEM)) 
was plotted against 
time. The sedative 
effect of CBZ (5 
mg/kg and 10 
mg/kg) compared 
to vehicle injection 
is seen as 
decreased 
locomotion over 
time for each 
genotype. Sedation 
was most 
prominent within 
the first 45 min and 
started to subside 
after about 60 min. 
Following vehicle injection mice became hyperactive and calmed down after about 45 min. 
Injection-related stress was observed in all conditions during the first 15 min.  B: Effect of CBZ 
on general activity and locomotion in C57BL/6J, FVB, abcb1a0/0 and abcc10/0 mice. Both were 
scored 15 - 45 min following injection. Top panels: Following CBZ (5 mg/kg) injection, general 
motor activity and locomotion were not altered in C57BL/6J mice but was significantly reduced 
in FVB, abcb1a0/0 and abcc10/0 mice. Bottom panels: After receiving a higher dose of CBZ (10 
mg/kg), mice from all genotypes showed significantly reduced general and locomotor activity. 
All results are presented as mean ± SEM, n = 8 per genotype. Statistics: post-hoc Bonferroni 
test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
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5.4.2 Development of chronic epilepsy following intra-
hippocampal kainic acid injection  
These experiments were performed in KA-treated NMRI, FVB and abcb1a0/0 mice 
during the phase of chronic recurrent seizures (see below). The doses of CBZ tested 
were higher than for assessing motor activity (20 mg/kg and 40 mg/kg). Under these 
conditions, all mice, independently of strain, were strongly sedated for up to 2 - 3 h 
after CBZ injection, confirming the results above.  
 
 
 
Figure 5.2: Effects of intrahippocampal KA injection in NMRI, FVB, abcb1a  and 
abcc1  mice. A: 
0/0
0/0 The morphological changes occurring 4 - 5 weeks post KA injection are 
shown in Nissl-stained sections; panels on the left side represent the non-injected, 
contralateral hippocampus (contra) and are compared to the injected, ipsilateral hippocampus 
(ipsi) represented on right side. Extensive cell loss in the KA-injected hippocampus can be 
seen in CA1, CA3 and the hilus of the dentate gyrus (DG), together with a marked dispersion 
of the dentate granule cells. Scale bar: 500 μm B: Examples of representative EEG recordings 
of spontaneous recurrent seizures in chronically epileptic mice. Paroxysmal rhythmic 
discharges typical of epileptic seizures are best seen at high temporal resolution. Seizure 
frequency and durations varied between individuals but no significant differences between 
genotypes could be determined (see Table 5-1). 
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As a consequence of KA injection, three distinct stages of seizure progression can be 
seen both morphologically and electrophysiologically in the mouse hippocampus 
(Bouilleret et al., 1999, Bouilleret et al., 2000, Riban et al., 2002). To analyse whether 
these changes occurred to a similar extent in the strains analysed here and to verify 
the placement of  electrodes, histological analysis was performed at the conclusion of 
the experiments, 4 – 5 weeks after KA injection (Figure 5.2 A), corresponding to the 
chronic phase (Bouilleret et al., 1999). Examination of Nissl-stained sections revealed 
no difference in hippocampus cytoarchitecture between genotypes; in all mice, 
extensive neuronal loss was evident in the hilus, CA1 and CA3 areas together with the 
prominent dispersion of the dentate granule cell layer characteristic of this model. 
These alterations were restricted to the dorsal hippocampus and no modifications 
were observed contralaterally, as reported previously (Bouilleret et al., 1999, Knuesel 
et al., 2001, Riban et al., 2002, Arabadzisz et al., 2005). EEG recordings performed 
during the chronic phase revealed that KA injection led to spontaneous recurrent 
seizures in all genotypes. Typically, the seizures started with high voltage sharp 
waves at low frequency followed by higher frequency lower voltage rhythmic spike-
and-wave activities characteristic of paroxysmal epileptic discharges (Figure 5.2 B). 
The frequency of seizures per minute and the duration of each seizure were 
comparable between genotypes but varied inter-individually and intra-individually 
between different days of recording. Strikingly, the inter-individual variability in FVB 
and abcb1a0/0 mice (6 – 8 fold differences) was higher than in NMRI mice (~ 3 fold 
differences). The length of seizures was similar for all genotypes (Table 5-1). 
Spontaneous seizures were observed during all experimental recording sessions, until 
the mice were sacrificed for histological analysis. 
 
Table 5-1: Seizure durations before and after treatment with vehicle or CBZ in the 
different genotypes  
genotype baseline vehicle CBZ (20 mg/kg) CBZ (40 mg/kg) 
NMRI 35.3 ± 14.1 25.5 ± 2.6 34.6 ± 9.2 40.9 ± 38.0 
FVB 24.6 ± 6.8 18.5 ± 4.3 21.7 ± 5.6 19.9 ± 4.6 
abcb1a0/0 25.5 ± 6.4 25.1 ± 7.3 28.8 ± 11.8 18.8 ± 3.7 
Results (in sec) are given as mean ± SD, n = 4 – 7 
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Figure 5.3: Analysis 
of EEG traces to 
quantify the 
antiepileptic action 
of CBZ in NMRI, 
FVB and abcb1a  
mice.
0/0
 A: 
Representative EEG 
traces for all strains 
after treatment with 
vehicle or CBZ (20 
mg/kg and 40 mg/kg 
respectively); in each 
case, the three traces 
are from the same 
animal. Seizure 
frequency and 
duration varied inter-
individually and intra-
individually on different days of recording and no significant strain differences could be 
detected. In NMRI mice frequent interictal spikes were observed after injection of 40 mg/kg of 
CBZ. In the FVB strain (WT and mutant), high frequency interictal spiking, especially after 
injection of 20 mg/kg of CBZ, was evident. B: Quantification of seizure frequency changes. 
Baseline frequency, before injection, was defined as 100%. Box plots represent the %-
changes of seizure frequency after injection compared to the baseline. Significant differences 
in seizure frequency compared to vehicle injection could not be found, except for NMRI mice. 
(post-hoc Bonferroni, ###P > 0.001). Compared to baseline, the seizure frequencies were 
significantly changed in NMRI mice after injection of 20 mg/kg and 40 mg/kg of CBZ as well as 
in FVB mice after injection of 20 mg/kg of CBZ (Wilcoxon, *P < 0.05, **P < 0.01) The number 
of mice evaluated for each condition ranged from four to seven.  
 
5.4.3 Seizure suppression by carbamazepine in 
abcb1a  and wild type mice 0/0
Following i.p. injection of vehicle, no significant difference in seizure frequency or 
duration was observed, indicating that the stress of handling and injection did not 
influence the occurrence of seizures (Figure 5.3 & Figure 5.4). Administration of a 
 81
Results: in vivo study Results 
 
therapeutic dose of CBZ (20 mg/kg, i.p.) which elicits acute sedation in NMRI, FVB, 
and abcb1a0/0 mice, failed to significantly suppress seizure activity in NMRI and 
abcb1a0/0 mice, compared to either vehicle or baseline (post-hoc Bonferroni, and 
Wilcoxon signed rank test) (Figure 5.3 B). Unexpectedly, a slight exacerbation of 
seizures was detected in NMRI mice (+39.6% ± 54.4% compared to baseline; 
Wilcoxon signed rank test, P < 0.05) which was seen in four out of six mice (Figure 
5.4). FVB mice exhibited a modest reduction in seizure frequency compared to 
baseline or maintained the same level (Figure 5.4), (on average -27.1% ± 9.5%, 
Wilcoxon signed rank test, P = 0.0078, Figure 5.3 B). However, compared to vehicle, 
the difference was not significant (post-hoc Bonferroni) due to variability of seizure 
frequency between recording sessions.  
 
 
Figure 5.4: Representations of individual seizure frequency changes after CBZ 
treatment. Capitalised letters represent individual mice. The seizure frequencies before and 
after injection of vehicle or CBZ are depicted for each mouse. Thus, frequency changes upon 
treatment can be seen. Frequencies before injection were obtained on the same day as after 
injection and served as baseline. 
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Finally, analysis of seizure duration revealed no effect of treatment or genotype (two-
way ANOVA, not significant) when compared to baseline or to vehicle (Table 5-1). 
Following the injection of a higher dose of CBZ (40 mg/kg), which induced prolonged 
sedation in all mice, a trend to a genotype effect (two-way ANOVA, F2,46 = 3.015, P = 
0.0588) and a treatment effect on seizure frequency was observed (F2,46 = 5.440, P = 
0.0076). Thus, seizure suppression was observed in NMRI mice with a decrease of 
92.8% ± 8.5% compared to baseline (Wilcoxon signed rank test, P = 0.0156). This 
finding was confirmed by the reduction in seizure frequency induced by CBZ 
compared to vehicle (Figure 5.4) and post-hoc Bonferroni analysis (P < 0.001; Figure 
5.3 B). Strikingly, these mice displayed frequent interictal spikes and bursts which, 
however, seldom evolved into seizures. FVB mice showed no significant change in 
seizure frequency at this dose; however, analysis of EEG traces also revealed a 
marked increase in the frequency and amplitude of interictal spikes (Figure 5.3 A), 
suggesting that CBZ alters network activity without suppressing seizures. In abcb1a0/0 
mice, CBZ treatment resulted in a consistent (Figure 5.4) but moderate decrease in 
seizure frequency compared to baseline. While observed in 4 out of 5 mice, the effect 
was statistically not significant (Wilcoxon signed rank test, P = 0.0625); likewise, no 
significant difference compared to vehicle injection could be detected (Figure 5.3 B). 
Analysis of seizure duration revealed no effect of CBZ irrespective of the genotype 
(Table 5-1), indicating that the drug does not influence a seizure once it has started.  
Altogether, the results indicate that CBZ modestly influences either ictal or interictal 
activity in the three strains of mice analysed. However, no clear involvement of 
Abcb1a expression could be observed in relation to AED resistance. 
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5.5 Discussion 
The present results demonstrate that the absence of either Abcb1a or Abcc1 does not 
influence the sedative side-effects of CBZ compared to the parental FVB strain, which 
lacks detectable Abcc2-immunoreactivity at the BBB (Soontornmalai et al., 2006). 
However, at low dose, CBZ has stronger sedative action in all lines derived from the 
FVB strain than in C57BL/6J mice, suggesting that the lack of Abcc2 expression in the 
BBB might underscore this effect, although the contribution of other genetic 
differences between FVB and C57BL/6J mice cannot be excluded. We also show that 
despite its prominent sedative effect in healthy and KA-treated mice, CBZ displays 
clear strain-specific differences in its antiepileptic action. At the highest dose tested, 
NMRI mice exhibited a marked reduction of seizure frequency compared to baseline 
and to vehicle. In contrast, CBZ was ineffective against seizures in FVB WT mice and 
produced only a minor reduction in abcb1a0/0 mutants. Altogether, these results 
suggest that lack of brain penetration of CBZ does not explain pharmacoresistance in 
this model of TLE.  
5.5.1 Differential sedative effects of carbamazepine  
To test whether multidrug transporters limit brain uptake of CBZ under normal 
physiological conditions, the sedative side effect of CBZ was measured in a test of 
general activity and locomotion. Both parameters were assessed to ensure that the 
reduction of locomotion were not due to CBZ-induced ataxia. Upon treatment with 
vehicle or low CBZ dose (5 mg/kg), mice showed an initial phase of hyperactivity 
followed by a phase of reduced locomotion, which appeared faster and was 
significantly stronger after CBZ than vehicle. At the higher CBZ dose (10 mg/kg), 
sedation was already apparent after 5 minutes, pointing to a rapid onset. Dose-
dependence was further evidenced by the profound sedation observed during the 
recording of EEG activity in epileptic mice treated with 20 mg/kg and 40 mg/kg.  
The effects of CBZ did not differ from vehicle after about 60 minutes, because mice 
show little spontaneous activity during the light (i.e. resting) circadian phase. Our 
results confirm previous studies reporting a dose-dependent reduction of general 
and/or locomotor activity following acute CBZ injection in NMRI mice (Redrobe and 
Bourin, 1999, Li et al., 2004). So far, however, no strain dependence of CBZ effects 
has been reported. Here, we show that FVB, abcb1a0/0, and abcc10/0 mice are more 
sensitive than C57BL/6J mice, which were sedated only at the higher dose of CBZ. 
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This effect is not due to an overall difference in motor activity between C57BL/6J and 
FVB mice, as the response to vehicle-injection was the same in the four lines tested. 
Most importantly, no difference was seen between FVB mice and abcb1a0/0 or abcc10/0 
mice. Therefore, the latter two transporters do not appear to significantly limit brain 
penetration of CBZ under physiological conditions. This conclusion extends previous 
pharmacological studies carried out in abcb1a0/0 and FVB WT mice, which reported no 
significant difference in serum and brain concentration of CBZ between the two 
genotypes (Owen et al., 2001a, Sills et al., 2002).  
5.5.2 Development of TLE upon KA injection is similar 
in all strains 
To study whether Abcb1a is involved in pharmacoresistance against CBZ, FVB and 
abcb1a0/0 mice were compared here to NMRI mice. As a prerequisite to this study, we 
verified that epileptogenesis and recurrent seizures are not different in mutant 
compared to WT mice. No differences among genotypes were observed in the 
response to KA injection after 4 – 5 weeks post-injection. The morphological changes 
in the three genotypes were similar and corresponded to previous findings (Bouilleret 
et al., 1999, Knuesel et al., 2001, Riban et al., 2002, Gouder et al., 2003, Arabadzisz 
et al., 2005). EEG recordings performed 3 weeks after KA injection also showed that 
all genotypes have spontaneous recurrent seizures with similar frequency and 
duration. FVB mice displayed, however, a higher inter-individual variability in seizure 
frequency with > 6 fold difference between the two extremes. Despite this fact, this 
mouse model appears well suited to study the role of multidrug transporters for 
pharmacoresistance in TLE. Furthermore, our observations confirm that abcb1a0/0 
mice have no apparent phenotype when they are not exposed systemically to 
potentially toxic substances (Schinkel et al., 1994). Although the BBB is disrupted 
locally during KA injection, this lesion is not aggravated by the general absence of 
Abcb1a (or Abcc2). Hence, these transporters are not involved in epileptogenesis per 
se. 
5.5.3 Does Abcb1a contribute to resistance against 
CBZ? 
Three weeks after intrahippocampal KA injection, during the chronic phase, CBZ (20 
or 40 mg/kg) or vehicle was administered during the EEG recording session to directly 
assess drug effect on seizure frequency. Despite the strong sedation induced by CBZ 
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in epileptic mice in the three genotypes tested, they all displayed pharmacoresistance 
at least to some degree. Unexpectedly, FVB mice were more sensitive to the sedative 
action of CBZ but more resistant to its antiepileptic action. These observations 
suggest that the mechanisms responsible for sedation and drug resistance are 
distinct. Further support for this concept comes from the observation that diazepam, 
acting as allosteric modulator of GABAA receptors, has a potent anti-epileptic effect in 
the KA mouse model of TLE at doses that produce no sedation (Riban et al., 2002). 
Thus, the sedative action of CBZ and diazepam are likely distinct. 
Due to the high inter-and intra-individual variability in seizure frequency, our primary 
measure of CBZ action was a change in seizure frequency compared to baseline. 
Administration of the 20 mg/kg dose of CBZ yielded contrasting effects in NMRI and 
FVB mice, with an exacerbation and a reduction of seizures, respectively. At 40 
mg/kg, a clear antiepileptic action was observed in NMRI mice, with seizures being 
replaced by increased interictal activity whereas FVB WT were unresponsive and 
abcb10/0 exhibiting a reduction in 4/5 mice. In previous studies, no effect of CBZ was 
observed in  NMRI mice up to 30 mg/kg (Riban et al., 2002, Gouder et al., 2003), 
suggesting that a very high dose of CBZ, made possible by the formulation used here, 
is required for suppressing seizures in this TLE model. Finally, the fact that no 
differences in seizure duration were found between genotypes before and after CBZ 
injection demonstrates that the drug does not influence a seizure once it has started. 
The resistance of FVB mice to CBZ again suggests that the genetic background plays 
a larger role than the possible absence of Abcc2 from the BBB in regulating seizure 
activity. Brain penetration of CBZ is evidenced by the increase of interictal activity 
seen in all strains upon treatment with 40 mg/kg CBZ. Nevertheless, in view of the 
fact that CBZ reduced seizure frequency compared to baseline in 4 out of 5 abcb1a0/0 
mice but none of the FVB WT mice suggests a possible contribution of Abcc1a to this 
effect. A similar trend was evident at the 20 mg/kg dose, with 3 out of 6 mutant mice 
exhibiting a reduction in seizure frequency. These results are supported by the 
observation that co-administration of the non-selective Abcb1 inhibitor verapamil in 
the pilocarpine rat model of TLE significantly potentiates the anticonvulsant activity of 
oxcarbazepine (Clinckers et al., 2005).  
Evidence for a contribution of ABC transporters of the BBB to pharmacoresistance in 
epilepsy mainly stems from human studies and from in vitro measurements with 
human ABC transporters. The present results, suggesting a modest contribution, at 
best of Abcb1a to CBZ pharmacoresistance might be due to species differences in 
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substrate recognition and transport, or to functional differences between human TLE 
and the KA-mouse model.  
5.5.4 Conclusions 
The present results reveal a possible contribution of Abcb1a to resistance against the 
anti-epileptic effects of CBZ in the KA mouse model, despite the fact that no 
contribution of this transporter to the sedative effects of CBZ could be detected. 
Changes in expression and/or function of ABC transporters might selectively occur in 
the epileptic focus, leading to enhanced function under pathological conditions. 
However, no clear involvement of an ABC transporter in pharmacoresistance to CBZ 
could be demonstrated here or in previous in vivo or in vitro work (Owen et al., 
2001a, Baltes et al., 2006). Therefore, additional mechanisms must be involved in 
pharmacoresistance. 
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6 General discussion 
6.1 Résumé 
With this work, we aimed to assess the validity of the hypothesis postulating that 
over-expression of multidrug transporters at the BBB are the main contributors to 
pharmacoresistance against AEDs. We have performed two independent studies to 
investigate the substrate specificities of the ABC transporters ABCB1 and ABCC1 for 
AEDs, and the in vivo role of Abcb1 for limited CBZ access to the brain. 
In the in vitro study, human ABCB1 and ABCC1 were inducibly expressed in MDCK 
cells and their capacity to transport either of the AEDs lamotrigine and CBZ across a 
cell monolayer was analysed by LC-MS/MS in a two-compartment cell culture system. 
As described extensively in chapter 4, we could not demonstrate that either drug is a 
substrate of ABCB1 or ABCC1. However, we observed a potent endogenous active 
transport system for these drugs, which could have masked a weak transport 
mediated by the recombinant proteins.  
The second study was performed in vivo. Wild type and transporter deficient mice 
were injected intrahippocampally with KA to induce pharmacoresistant TLE. The 
impact of transporter deficiency on CBZ sensitivity was assessed by analysing seizure 
numbers upon injection with CBZ in the chronic phase of TLE. A previous study from 
our lab (Soontornmalai, 2006) on the sedative effect of low doses of CBZ in healthy 
mice found no enhanced sedation due to lack of Abcb1a or Abcc1. However, with the 
lowest dose, a strain difference between C57BL/6 and mice of the FVB background 
was observed. This could be due to the lack of Abcc2 in the BBB of the FVB 
background. As elaborated in chapter 5, a strong sedative side effect of higher doses 
of CBZ was observed also in epileptic mice of all tested genotypes, confirming the 
previous data. Nevertheless, in respect to treatment of epilepsy with CBZ we 
observed strain differences as well; however, we were not able to clearly allocate this 
effect to the presence or absence of Abcb1a. Strikingly, an effect of CBZ on epileptic 
activity was observed in all strains to some extent. Hence, no marked limitation of 
CBZ uptake into the brain was detected. EEG patterns after CBZ treatment revealed 
more interictal spiking than after vehicle treatment, especially in NMRI mice which 
also displayed less seizures upon injection with a high dose of CBZ. These strain-
specific differences in CBZ action, as well as strain-specific expression patterns of ABC 
transporters are possibly connected. Therefore pharmacoresistance in the KA mouse 
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model may have something to do with multidrug transporter expression in the BBB or 
BCSFB to some extent. Taken together, these results showed a very strong sedative 
action of CBZ in mice, which seems stronger than in human patients. The sedative 
action seems to arise already at very low doses of the drug, whereas the seizure 
suppressive action, as seen in the NMRI mice, was only evoked at a rather high dose. 
Yet, despite the seizure number being markedly reduced in these mice, their EEG 
pattern did not resemble one of a healthy mouse as demonstrated by Arabadzisz et 
al. (2005), but rather displays a lot of interictal spiking. To sum up, CBZ has an effect 
on the healthy brain as well as on the epileptic brain. The question remains, whether 
the evoked interictal spiking activity, was observed at high doses of the drug, is 
beneficial or rather detrimental. Additionally, it is not clear if this effect is also seen in 
human patients or if it is characteristic for the mouse model. 
6.2 Methodological considerations 
6.2.1 Cell culture study: 
We used MDCK cells which were transfected with a vector containing an expression 
cassette to transcribe an ABC transporter and eGFP under the control of a bi-
directional, inducible promoter. The great advantage of an inducible expression 
system was that the same cell clone, from the same aliquot with the same number of 
passages could be used as baseline control, and to study the effect of transporter 
expression. This ensured that expression of endogenous proteins was the same in 
both conditions. Therefore, baseline active transport and passive diffusion was in the 
same range, leading to reliable, robust results with little variations. Potential diverging 
differentiation of sub-clones due to separate culturing could be ruled out. Hence, the 
best possible baseline was achieved, thus providing for high reproducibility of the 
results. Therefore the BBB model we developed is well suited to conduct AED 
transport studies. 
Despite the generation of monoclonal cell lines, we observed, upon induction of gene-
expression with DOX, a mosaic-like expression of eGFP as well as ABC transporters 
which was not congruent. Hence, the co-expression of eGFP could not be used as 
quantitative marker for transporter expression as originally planned, but only to check 
for induced gene-expression upon addition of DOX. Retrospectively, it might have 
been better not to use such a bi-directional expression system as the benefit from 
eGFP expression was only minor and the over-expression of eGFP in addition to the 
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transporter could have unnecessarily stressed the cells. Cloning of the constructs was 
also quite difficult and may have been easier without the bi-directional promoter and 
eGFP. 
No transport of either lamotrigine or CBZ was found, however, a weak effect could 
have been overlooked. In this line it has to be considered that we can not be certain 
that all transporters are fully functional despite proper localisation. By over-expression 
a lot more transporters are produced than would be in a physiological surrounding. 
Therefore, a limitation of necessary co-factors for individual transporters could arise 
due to titration of the supplies. In this case, weak transport by only few functional 
transporters may be missed. Another possibility are missing interaction partners or 
signals which would lead to functional changes e.g. caused by a pathology, which in 
turn would allow efficient drug-extrusion by ABCB1 or ABCC1. Furthermore it has to 
be noted that transport was only measured over a limited surface area of 0.33 cm2 in 
our case, whereas the surface area of the murine BBB is much larger, hence, also a 
weak effect, which might be missed in the experimental setup, can have an impact in 
vivo.  
MDCK cells were chosen as they form tight monolayers which are easy to cultivate 
and transfect and have been used before in similar drug-transport studies. While 
being well suited for such applications, a few disadvantages have to be kept in mind. 
Due to their origin (from the kidney nephron) and original function (extrusion of 
xenobiotics and toxins), they express a vast array of endogenous transporters (Goh et 
al., 2002). The exact expression pattern is, to our knowledge, not completely 
characterised. The expression of endogenous transporters may be problematic as 
they might be more efficient in transporting a compound to be tested than the 
recombinantly expressed protein, thereby masking effects of the latter. Nevertheless, 
using another cell line would not have solved this problem. The approach to use 
immortalised brain endothelial cells was not suitable in our experiments as the 
available endothelial cell lines do not display high enough impermeability mediated by 
tight junctions which is fundamental for the assessment of transcellular transport 
(Deli et al., 2005). The use of primary endothelial cells was no option either due to 
two reasons. On one hand, they cannot be cultivated over prolonged periods of time, 
which is essential for stable transfections followed by transport studies, and on the 
other hand, only grow to tight enough monolayers when cultivated in contact with 
astrocytes (Deli et al., 2005). However, this would impede with the transport studies, 
as two cell layers would have to be crossed. Additionally, all cells which are suitable to 
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perform transport studies come from tissue which is involved in selective uptake or 
extrusion processes and therefore express a range of endogenous transporters. So 
far, the only way to overcome this problem is to use inhibitors which are reasonably 
specific. This stresses again the need for a good baseline control, which our system 
could offer. 
6.2.2 Animal study: 
The intrahippocampal KA mouse model of TLE led to robust results. If the correct 
amount of KA was injected into the right location of the brain the lesion and chronic 
seizures in all mice were comparable. Thus, it is a good system to study epilepsy 
treatment across genotypes. 
Nevertheless, there are some concerns also with this system. The main one is, as with 
all animal models of diseases, the validity. To what extent does an animal model 
mimic the real phenotype found in humans? One can only speculate, and try to work 
with the best system available.  
There are some technical difficulties which had to be considered. Not all animals 
which had been operated could be analysed due to loss of electrodes before or during 
the experiment or to absence of or bad EEG signals because of faulty electrodes or 
absence of seizures due to misplaced KA injection. We aimed to measure at least 5 
animals per genotype and condition to have a high enough n for statistical analyses. 
According to our experience it was thus necessary to operate three times more 
animals than the finally desired number, in our case at least 15 mice per genotype. 
A somewhat unexpected problem was the size of the abcb1a0/0 mice. So far this 
mouse line has not been characterised extensively. It was therefore surprising to find 
that most mice of this strain barely weighed 20 g, even after 4 – 6 months of age. 
This complicated the experiments as the mice reacted much more sensitive to the KA 
injection, sometimes even displaying convulsive SE after injection of the correct 
amount of KA. Also FVB mice were more sensitive to KA and the mortality after 
anaesthesia and during SE was rather high compared to mice of the NMRI strain. 
Additionally, abcb1a0/0 mice displayed hyperactivity compared to WT mice. This had 
two implications: They tended to lose their electrodes more frequently than the WT 
and had more moving artefacts during EEG recordings, especially after vehicle 
injection. It was also observed that the transporter-deficient mice were difficult to 
breed. They displayed seasonal variations and generally only small litters.  
 92 
  General discussion 
For best results in the EEG recordings, we tried to minimise moving artefacts by 
surveying the animals during the light period (resting phase of the mice) and without 
food or water in the chambers. Nevertheless, artefacts could not completely be 
avoided. A time frame with as little artefacts as possible, but not too long after drug-
injection, was defined for each animal and condition, to evaluate seizure number and 
duration. Depending on the localisation of the bipolar electrodes in respect to the 
epileptic focus the amplitudes of seizures were varying and in many cases getting 
lower over time. These challenges may also be the reason that not many quantitative 
studies of seizure analysis have been published so far. To improve EEG recordings 
and reduce moving artefacts based on movement of the cables, it would be best to 
use a telemetry system. This would also allow 24 h surveillance. However, at the 
timepoint when this study was started, such a system was not available in the lab.  
6.3 Are the results from the two studies 
comparable? 
The combination of assays in a cell culture system with inducible over-expression of 
human transporters and analysis in WT and transporter-deficient animals was used to 
test two fundamental properties, to give a more global picture of transporter function. 
i) Are the drugs substrates of ABC transporters; and ii) Are transporter-deficient mice 
more sensitive to drug treatment than WT mice? The advantages and disadvantages 
of the two approaches were thought to complement and balance each other out. 
While in vitro assays lack some of the complex interactions which would happen in 
the physiological context, the opposite argument can be used against in vivo studies. 
As observed in our study, there may be marked strain differences which make the 
interpretation of a result complicated. The complexity of a whole organism is 
problematic as it is difficult to assign a specific phenotype to a single mechanism or 
molecule. Let alone the question as to what extent an animal model really represents 
a human disease and the findings can be applied to the disease. If the two studies 
would have a clear, ‘yes or no’, outcome, the interpretation would be easy. However, 
the in vitro work seems to rule out an involvement of human ABC transporters in AED 
resistance whereas the results from the in vivo work do not completely. This could be 
explained by the possibility that the transporters from mice and men do not have the 
same substrate specificity. This has been speculated before and was assessed by 
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Baltes et al. (2006). It has to be noted that the candidate which seems most 
promising form the in vivo studies, Abcc2, was not tested in vitro so far. 
Another possible explanation which could partly explain the discrepancies between 
the two studies is the hypothesis that substrate specificity may be regulated by the 
pathology. In this case our results would argue against an onset of 
pharmacoresistance in TLE upon upregulation of transporter expression as suggested 
by Dombrowski et al. (2001) and Kubota et al. (2006) but rather for functional 
changes, possibly through post-translational modifications, which could lead to 
enhanced transport of AEDs upon onset of TLE.  
However, to our knowledge, for both studies the best available, reliable systems were 
used. Hence, the fact that no clear involvement in drug export of either transporter 
could be demonstrated in vitro or in vivo, hints that the tested transporters are not, or 
only to a minor degree involved in resistance to the drugs tested. In this respect the 
two approaches are comparable and complement each other. 
6.4 Validity of the multidrug transporter 
hypothesis of pharmacoresistance in TLE 
From the results of this work it seems unlikely that ABCB1 and ABCC1 are involved to 
resistance to the AEDs lamotrigine and CBZ. The possibility of masked transport 
through other means in the in vitro study and the involvement of transporter-
deficiency on the genotype-specific effect of CBZ in vivo point to minor involvement at 
most. To proof that a specific transporter is responsible for the transport of a certain 
drug, a strong effect in vitro and in vivo would be expected. Evidence, supporting our 
findings, which rules an involvement of ABC transporters in AED resistance out, is 
accumulating. While Owen et al. (2001) and Potschka et al. (2003) could not 
demonstrate involvement of ABCB1 or Abcc2 in resistance to CBZ and lamotrigine 
respectively, Cerveny et al. (2006) could not demonstrate ABCG2 involvement either. 
Baltes et al. (2007) showed that neither ABCB1, ABCC1 nor ABCC2 are not involved in 
transport of valproic acid. Nevertheless, proteins from other families could be the 
main players and a concerted action of several transporters may possibly occur at the 
BBB and also the BCSFB. One candidate is the non-ABC multi-specific transporter 
RLIP76 which has been shown to transport the two AEDs phenytoin and CBZ (Awasthi 
et al., 2005). However, all together, it seems that the transporter hypothesis of AED 
resistance in TLE had been emphasised too strongly in the past. Most probably, AED 
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extrusion by ABC or other transporters is not the main and certainly not the only 
mechanism. The facts that AED resistance includes many different compounds and 
most TLE patients are affected but not all, suggest that several resistance 
mechanisms act individually or in concert and may vary from case to case. Some 
evidence for all hypotheses which have been put forward so far, the transporter 
hypothesis, the enzyme hypothesis and the drug-target hypothesis, has been 
published. While researchers try to verify their hypothesis, looking for one effect, they 
may miss others, especially in animal models. Hence, multiple mechanisms acting 
together to sustain pharmacoresistance could also mask effects of transporter 
depletion. Therefore no clear ‘yes or no’ answers could be found, also in our work. It 
seems naïve to believe that all possible mechanisms have been identified. Some 
mechanisms contributing to pharmacoresistance of one or another compound in one 
or another patient may still remain to be discovered. 
Several polymorphisms are known for ABC transporters and it has been demonstrated 
that these may display functional differences e.g. in substrate recognition (Kimchi-
Sarfaty et al., 2007). It is therefore possible that the cDNA of the allele we used for 
our recombinant expression system is less sensitive to CBZ and lamotrigine than 
another one would be. In this respect it might be interesting to analyse the genotypes 
of patients with or without pharmacoresistance. In recent years, several groups have 
tried to address the impact of pathology induced genomic responses, i.e. changes of 
gene expression profiles, using gene chip based molecular profiling of tissue from TLE 
patients or animal models (Majores et al., 2004). Others have tried to assign certain 
polymorphisms to TLE, however, most of this data has yet to be replicated (Cavalleri 
et al., 2005). Besides, so far, most associations of polymorphisms in patients or 
changes of gene expression were made in respect to pathogenesis and data in 
respect to pharmacoresistance is largely lacking, except for data supporting the 
transporter hypothesis on ABCB1 (Zimprich et al., 2004). Based on the finding that 
this hypothesis is not the most important for pharmacoresistance, genotype analysis 
should be directed towards other candidates in the future. 
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6.5 Future directions 
Epilepsy is still a major neurological disorder of which only little is understood. To 
improve the quality of life of patients, the development of better tolerable treatments 
with fewer side effects is necessary. Generally, in depth understanding of all different 
types of epilepsy will be necessary for future development of therapies or even cures. 
Therefore, it has been and will also be necessary in the future to combine various 
approaches of research: animal models, molecular approaches in vitro, and analysis of 
data from patients. Together, this will hopefully lead to the design of a new 
generation of effective treatments. 
In respect to the transporter hypothesis of pharmacoresistance in TLE additional 
experiments could be carried out to identify the key players. Both systems used in 
this work can be further developed and modulated. With the intrahippocampal KA 
mouse model of TLE, it would also be possible to study the effect of other AEDs on 
seizures in wild type and transporter deficient mice, also of other genotypes. With the 
existing cell culture system it would be easy to test for transport of other AEDs and 
further cell lines could be generated, expressing other candidates for AED transport, 
such as ABCG2 (BCRP), OATs or RLIP76.  
To overcome the problem of effects by unknown endogenous transporters it may be 
necessary to establish totally novel cell culture systems, using cells which lack 
endogenous transporters. Such cells may have the downside not to form tight 
junctions. In this case it may be possible to transfect them not only with the 
transporter of interest, but additionally with all genes needed for the generation of 
tight junctions, thus creating cells with can build tight monolayers while expressing 
only the transporter of interest. 
With respect to the fact that the transporter hypothesis is probably not the main 
factor leading to AED resistance, the main focus of future research should lie on the 
examination of other mechanisms. This, especially in respect to future drug-
development, to find compounds with better efficacy and fewer side effects. The 
recent approaches to use co-treatment of AEDs with transporter-inhibitors seems not 
a good option due to strong side effects of the inhibitors and little benefit, especially 
since the effect of the transporters may not be as pronounced as previously thought. 
The impact of enzymes at the BBB or BCSFB on AED resistance will have to be 
investigated as well. If enzymes are the key players, their blockage might be a 
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possible strategy for treatment. However, side effects would also be an issue of 
concern in this case. 
Pharmacoresistance is likely to underlie transcriptional and post-transcriptional 
regulations or functional changes occurring upon development of TLE and seizures. 
Hence, an important direction of research must lie in the understanding of functional 
alterations of drug targets due to genetic variations or pathological changes. In this 
respect genotype analysis of healthy subjects and epileptic patients may reveal new 
insights on the pathology itself as well as the underlying pharmacoresistance. If novel 
candidates are defined in such an approach, these can then be further investigated as 
to what their involvement is in pharmacoresistance and by which mechanisms they 
act. Based on this, it should then be possible to develop novel drugs with different 
modes of actions or targets and to which the patients will be responsive. 
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8 Abbreviations 
 
a apical 
ABC ATP-binding cassette 
ABCB ABC transporter subfamily B 
ABCC ABC transporter subfamily C 
ABCG ABC transporter subfamily G 
Ach achetylcholine, neurotransmitter 
ADP adenosine diphsphate, a nucleotide 
AED antiepileptic drug 
ANOVA analysis of variance 
ATP adenosine triphosphate, a nucleotide 
AUC area under the curve 
BBB blood-brain barrier 
BCRP brest cancer resistant protein 
BCSFB brain-CSF barrier 
bl basolateral 
BUI brain uptake index 
CA cornu ammonis, part of the hippocampus proper 
CBZ carbamazepine, AED 
CE collision energy 
CNS central nervous system 
CP choroid plexus 
CSF cerebrospinal fluid 
cTR corrected transport ratio 
CXP collision cell exit potential 
DG dentate gyrus, part of the hippocampal formation 
DMSO dimethyl sulfoxide 
DOX doxycycline 
DP declustering potential 
EEG electroencephalography 
EP entrance potential 
ESI electrospray ionisation 
GABA γ-amminobutyric acid, neurotransmitter 
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HPLC high pressure/performance liquid chromatography 
HS hippocampal sclerosis 
ICC immunocytochemistry 
KA kainic acid or kainate 
LC liquid chromatography 
LC-MS/MS liquid chromatography coupled mass spectrometry 
LOD limit of detection 
LOQ limit of quantification  
MDCK cells Madin-Darby canine kidney cells 
MDR multidrug resistance 
MRM multiple reaction monitoring  
MRP multidrug resistance protein, multidrug resistance-associated protein 
MS mass spectrometry 
MSD membrane spanning domain 
NBD nucleotide binding domain 
OAT organic anion transporter (a family of transporters) 
OATP organic anion transporter protein (a family of transporters) 
PBS phosphate-buffered saline  
P-gp P glycoprotein 
RT room temperature 
SE status epilepticus 
TEER trans-endothelial (or epithelial) electrical resistance 
TJ tight junctions 
TLE temporal lobe epilepsy 
TM transmembrane 
TMD transmembrane domain 
TR transport ratio 
WT wild type 
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